Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treatment of diseases and disorders
By developing deuterium-enriched piperidinyl-methyl-purine amine compounds to inhibit NSD2 activity, the problem of insufficient effectiveness and significant side effects of existing cancer treatments is solved, providing a new approach to treating NSD2-related diseases.
Patent Information
- Application Number
- CN202380022643.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-05
- Filing Date
- 2023-01-05
- Publication Date
- 2024-11-26
AI Technical Summary
Existing cancer treatments are ineffective for some patients and have serious side effects, necessitating new therapies to inhibit nuclear receptor binding to SET domain protein 2 (NSD2) to treat NSD2-related diseases or conditions, such as cancer.
Deuterium-enriched piperidinyl-methyl-purineamine and related compounds were developed to inhibit NSD2 activity and administered to subjects via pharmaceutical compositions to treat related diseases or conditions.
It effectively inhibits the activity of NSD2, providing a treatment option for NSD2-related diseases or conditions and reducing the side effects of traditional treatments.
Smart Images

Figure BDA0005000435290000021 
Figure BDA0005000435290000031 
Figure BDA0005000435290000061
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 296,676, filed on January 5, 2022, the entire contents of which are hereby incorporated by reference. Field of the Invention
[0003] The present invention provides deuterium-enriched piperidinyl-methyl-purine amines and related compounds, pharmaceutical compositions, their use for inhibiting NSD2, and their use in treating diseases or disorders such as cancer. Background Art
[0004] Despite the extensive research efforts and scientific advances reported in the literature in the treatment of cancer, cancer remains a significant health problem. Solid tumors, including prostate cancer, breast cancer, and lung cancer, remain very common in the world's population. Current treatment options for these cancers are not effective for all patients and / or can have severe adverse side effects. New therapies are needed to address this unmet need in cancer treatment.
[0005] Nuclear receptor binding SET domain protein 2 (NSD2), also known as multiple myeloma SET domain (MMSET) or Wolf-Hirschhorn syndrome candidate 1 (WHSC1), is an epigenetic modifier that plays a role in tumorigenesis. Several human cancers are associated with NSD2 overexpression and / or activating point mutations (Coussens et al., J.Biol.Chem.293 (2018) 13750-13654). For example, high expression of NSD2 in human cancers (including bladder cancer, brain cancer, gastrointestinal cancer, lung cancer, liver cancer, ovarian cancer, skin cancer, uterine cancer, breast cancer, prostate cancer and glioblastoma) has been reported. In addition, the pediatric cancer genome seems particularly likely to contain NSD2 mutations. Finally, the upregulation of NSD2 has been associated with aggressive tumor behavior and poor clinical outcomes. Certain compounds that inhibit NSD2 are described in International Patent Application Publication WO2021 / 028854. Additional compounds that inhibit NSD2 would be beneficial to patients suffering from NSD2-associated diseases or disorders.
[0006] The present invention satisfies the above-identified needs and provides other related advantages. SUMMARY OF THE INVENTION
[0008] The present invention provides deuterium-enriched piperidinyl-methyl-purine amines and related compounds, pharmaceutical compositions, their use for inhibiting NSD2, and their use in treating diseases or conditions (such as cancer). Specifically, one aspect of the present invention provides a group of deuterium-enriched piperidinyl-methyl-purine amines and related compounds, such as compounds represented by Formula I:
[0009]
[0010] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in the Detailed Description. Further description of deuterium-enriched piperidinyl-methyl-purine amines and additional collections of related compounds are described in the Detailed Description. The compound may be a component of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
[0011] Another aspect of the invention provides a group of difluoromethylketone-substituted piperidinyl-methyl-purine amines and related compounds, including deuterium-enriched compounds, such as compounds represented by Formula II:
[0012]
[0013] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in the Detailed Description. Further description of additional classes of difluoromethylketo-substituted piperidinyl-methyl-purine amines and related compounds are described in the Detailed Description. The compounds may be a component of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
[0014] Another aspect of the present invention provides a method of treating a disease or condition mediated by NSD2 in a subject. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound described herein (such as a compound of Formula I or II) to treat the disease or condition, as further described in the detailed description.
[0015] Another aspect of the present invention provides a method of inhibiting the activity of nuclear SET domain-containing protein 2 (NSD2). The method comprises contacting NSD2 with an effective amount of a compound described herein (such as a compound of Formula I or II) to inhibit the activity of NSD2, as further described in the detailed description. DETAILED DESCRIPTION OF THE INVENTION
[0017] The present invention provides deuterium-enriched piperidinyl-methyl-purine amines and related compounds, pharmaceutical compositions, their use for inhibiting NSD2, and their use in treating diseases or disorders (such as cancer). Unless otherwise indicated, the practice of the present invention employs conventional techniques of organic chemistry, pharmacology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology. Such techniques are explained in the literature, such as in "Comprehensive Organic Synthesis" (BM Trost and I. Fleming, ed., 1991-1992); "Handbook of experimental immunology" (DM Weir and CC Blackwell, ed.); "Current protocols in molecular biology" (FM Ausubel et al., ed., 1987, and regularly updated); and "Current protocols in immunology" (JE Coligan et al., ed., 1991), each of which is incorporated herein by reference in its entirety.
[0018] Deuterium enriched refers to the characteristic that a compound has an amount of deuterium greater than a naturally occurring compound or a synthetic compound prepared from a matrix having a naturally occurring isotopic distribution. In some cases in this disclosure, a threshold amount of deuterium enrichment is specified, and all percentages given for the amount of deuterium present are molar percentages.
[0019] deuterium( 2 H) Yes 1 H is a stable, non-radioactive isotope of hydrogen and has an atomic weight of 2.014. Hydrogen occurs naturally as an isotope 1 H hydrogen (i.e., protium), deuterium ( 2 H) and tritium ( 3 H) exists in a mixture. The natural abundance of deuterium is 0.015%. Those skilled in the art recognize that in all chemical compounds containing H atoms, H atoms actually represent 1 H Hydrogen, Deuterium ( 2 H) and tritium ( 3 H), of which about 0.015% is deuterium. Therefore, a compound having deuterium levels that have been enriched to greater than 0.015% of its natural abundance would be considered unnatural, and therefore novel compared to its unenriched counterpart.
[0020] Various aspects of the invention are described in the following subsections; however, aspects of the invention described in a particular section are not limited to any particular section. In addition, when a variable is not accompanied by a definition, the previous definition of the variable shall prevail.
[0021] definition
[0022] Compounds of the present invention include compounds generally described herein, and are further described by the categories, subclasses, and species disclosed herein. As used herein, the following definitions apply unless otherwise noted. Unless otherwise noted, these definitions apply, regardless of whether a term is used alone or in combination with other terms. Therefore, the definition of "alkyl" applies to "alkyl" and "-O-alkyl" and the like "alkyl" moieties. For purposes of the present invention, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics (75th edition). In addition, the general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th edition, edited by Smith, MB and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
[0023] As used herein, the term "aliphatic" or "aliphatic group" refers to a straight (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is fully saturated or contains one or more unsaturated units, or a monocyclic or bicyclic hydrocarbon that is fully saturated or contains one or more unsaturated units, but is not aromatic (also referred to herein as "cycloaliphatic"), which has a single point of attachment to the rest of the molecule. Unless otherwise indicated, an aliphatic group contains 1-6 aliphatic carbon atoms. In certain embodiments, an aliphatic group contains 1-5 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-4 aliphatic carbon atoms. In yet other embodiments, an aliphatic group contains 1-3 aliphatic carbon atoms, and in yet other embodiments, an aliphatic group contains 1-2 aliphatic carbon atoms. In certain embodiments, "cycloaliphatic" refers to a monocyclic C3-C6 hydrocarbon that is fully saturated or contains one or more unsaturated units, but is not aromatic, which has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
[0024] The term "bicyclic" or "bicyclic system" as used herein means any bicyclic system, that is, carbocyclic or heterocyclic, saturated or with one or more unsaturated units, with one or more common atoms between the two rings of the ring system. Therefore, the term includes any allowed ring fusion, such as ortho-fusion or spirocyclic. The term "heterobicyclic" as used herein is a subset of "bicyclic", which requires one or more heteroatoms to be present in one or both rings of the bicyclic. Such heteroatoms may be present in the ring connection and may be optionally substituted, and may be selected from nitrogen (including N-oxides), oxygen, sulfur (including oxidized forms such as sulfones and sulfonates), phosphorus (including oxidized forms such as phosphates), boron, etc. In certain embodiments, the bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. The term "bridged bicyclic" as used herein means any bicyclic ring system, that is, carbocyclic or heterocyclic, saturated or partially unsaturated, with at least one bridge. As defined by IUPAC, "bridge" is an unbranched atomic chain or atom or valence bond connecting two bridgeheads, wherein "bridgehead" is any backbone atom of a ring system, which is bonded to three or more backbone atoms (excluding hydrogen). In certain embodiments, a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. Such bridged bicyclic groups are well known in the art, and include those groups described below, wherein each group is attached to the remainder of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise noted, a bridged bicyclic group is optionally substituted by one or more substituents described for an aliphatic group. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bicyclics include:
[0025]
[0026] Exemplary bridged bicyclic rings include:
[0027]
[0028] The term "lower alkyl" means C 1-4 Straight or branched chain alkyl groups. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.
[0029] The term "lower haloalkyl" refers to a C 1-4 Straight or branched chain alkyl groups.
[0030] The term "heteroatom" refers to one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen; or a substitutable nitrogen of a heterocyclic ring, such as N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR+ (as in N-substituted pyrrolidinyl)).
[0031] As used herein, the term "unsaturated" refers to a moiety having one or more units of unsaturation.
[0032] As used herein, the term "divalent C 1-8 (or C 1-6 ) saturated or unsaturated, straight or branched hydrocarbon chain” means a straight or branched divalent alkylene, alkenylene and alkynylene chain as defined herein.
[0033] The term "alkylene" refers to a divalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., -(CH2) n -, wherein n is a positive integer, preferably 1-6, 1-4, 1-3, 1-2, or 2-3. A substituted alkylene chain is a polymethylene chain in which one or more methylene hydrogen atoms are replaced by a substituent. Suitable substituents include the substituents described below for substituted aliphatic groups.
[0034] The term "-(C0 alkylene)-" represents a bond. Thus, the term "-(C0 alkylene)-" 0-3 "alkylene)-" encompasses a bond (i.e., C0) and -(C 1-3 alkylene)-group.
[0035] The term "alkenylene" refers to a divalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced by a substituent. Suitable substituents include the substituents described below for substituted aliphatic groups.
[0036] The term "halogen" refers to F, Cl, Br or I.
[0037] The term "aryl", used alone or as part of a larger moiety (such as in "aralkyl", "aralkyloxy" or "aryloxyalkyl"), refers to a monocyclic or bicyclic ring system having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, and wherein each ring in the system contains 3-7 ring members. The term "aryl" can be used interchangeably with the term "aryl ring". In certain embodiments of the present invention, "aryl" refers to an aromatic ring system, which includes but is not limited to phenyl, biphenyl, naphthyl, anthracenyl, etc., which may carry one or more substituents. The scope of the term "aryl" as used herein also includes groups in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimide, naphthimidyl, phenanthridinyl or tetrahydronaphthyl, etc. The term "phenylene" refers to a polyvalent phenyl group having an appropriate number of open valences to account for the groups attached to it. For example, when it has two groups attached to it, "phenylene" is a divalent phenyl group (e.g., ); when it has three groups attached to it, "phenylene" is a trivalent phenyl group (e.g., ). The term "arylene" refers to a divalent aromatic group.
[0038] The terms "heteroaryl" and "heteroar-", used alone or as part of a larger moiety (e.g., "heteroaralkyl", or "heteroaralkoxy"), refer to groups having 5 to 10 ring atoms, preferably 5, 6 or 9 ring atoms; having 6, 10 or 14 π electrons shared in a cyclic array; and having 1 to 5 heteroatoms in addition to carbon atoms. The term "heteroatom" refers to nitrogen, oxygen or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of basic nitrogen. Heteroaryl groups include, but are not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl and pteridinyl. As used herein, the terms "heteroaryl" and "heteroaryl-" also include groups in which a heteroaromatic ring is fused to one or more aryl rings, cycloaliphatic rings, or heterocyclyl rings, wherein, unless otherwise indicated, the residue or point of attachment is located on the heteroaromatic ring or on one of the rings fused to the heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolyl, and tetrahydroisoquinolyl. The heteroaryl group may be monocyclic or bicyclic. The term "heteroaryl" may be used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," wherein any of the terms include optionally substituted rings. The term "heteroaralkyl" refers to an alkyl group substituted with a heteroaryl, wherein the alkyl and heteroaryl portions are independently optionally substituted.
[0039] The term "heteroarylene" means a polyvalent heteroaryl group with an appropriate number of open valences to account for the groups attached to it. For example, when it has two groups attached to it, a "heteroarylene" is a divalent heteroaryl group; when it has three groups attached to it, a "heteroarylene" is a trivalent heteroaryl group. The term "pyridinylene" means a polyvalent pyridine residue with an appropriate number of open valences to account for the groups attached to it. For example, when it has two groups attached to it, a "pyridinylene" is a divalent pyridine residue (e.g., ); when it has three groups attached to it, a "pyridylene" is a trivalent pyridine residue (e.g., ).
[0040] As used herein, the terms "heterocycle", "heterocyclyl", "heterocyclic residue" and "heterocyclic ring" are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic moiety which is saturated or partially unsaturated and has, in addition to carbon atoms, one or more, preferably one to four heteroatoms as defined above. The term "nitrogen" when used with respect to a ring atom of a heterocycle includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or + NR (as in N-substituted pyrrolidinyl).
[0041] The heterocyclic ring may be attached to its side group at any heteroatom or carbon atom that results in a stable structure, and any of the ring atoms may be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic residues include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxane, dioxolane, diazepine, pyrrolidine ... Oxaza Base, thiazolyl The term "heterocycle", "heterocyclyl", "heterocyclyl ring", "heterocyclic group", "heterocyclic moiety" and "heterocyclic residue" are used interchangeably herein and also include groups wherein the heterocyclyl ring is fused to one or more aryl, heteroaryl or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl or tetrahydroquinolinyl. The heterocyclyl group may be monocyclic or bicyclic. The term "heterocyclylalkyl" represents an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl moieties are independently optionally substituted. The term "oxo-heterocyclyl" represents a heterocyclyl substituted by an oxo group. The term "heterocyclylene" represents a polyvalent heterocyclyl group having an appropriate number of open valences to account for the group to which it is attached. For example, when it has two groups attached to it, "heterocyclylene" is a divalent heterocyclyl group; when it has three groups attached to it, "heterocyclylene" is a trivalent heterocyclyl group.
[0042] As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties as defined herein.
[0043] As described herein, the compounds of the present invention may contain "optionally substituted" parts. In general, the term "substituted", whether or not there is the term "optionally" in front, means that one or more hydrogens of the specified part are replaced by suitable substituents. Unless otherwise specified, the "optionally substituted" group can have suitable substituents at each substitutable position of the group, and when more than one position in any given structure can be substituted by more than one substituent selected from a specified set, the substituents at each position can be the same or different. The substituent combinations considered by the present invention are preferably those substituent combinations that can form stable or chemically feasible compounds. The term "stable" used herein refers to a compound that does not substantially change when undergoing conditions that allow it to be produced, detected, and in certain embodiments recovered, purified, and used for one or more purposes disclosed herein.
[0044] Each optional substituent on a substitutable carbon is independently selected from the following monovalent substituents: halogen; -(CH2) 0- 4R o ; -(CH2) 0-4 OR o ; -O(CH2) 0-4 R o 、-O-(CH2) 0-4 C(O)OR o ; -(CH2) 0-4 CH(OR o )2; -(CH2) 0-4 SR o ; -(CH2) 0-4 Ph, which can be o Substitution; -(CH2) 0-4 O(CH2) 0-1 Ph, which can be o Substitution; -CH=CHPh, which can be replaced by R o Substitution; -(CH2) 0-4 O(CH2) 0-1 -pyridyl, which may be R o Substitution; -NO2; -CN; -N3; -(CH2) 0-4 N(R o )2; -(CH2) 0- 4N(R o )C(O)R o ;-N(R o )C(S)R o ; -(CH2) 0-4 N(R o )C(O)NR o 2;-N(R o)C(S)NR o 2;-(CH2) 0-4 N(R o )C(O)OR o ;-N(R o )N(R o )C(O)R o ;-N(R o )N(R o )C(O)NR o 2;-N(R o )N(R o )C(O)OR o ;-(CH2) 0-4 C(O)R o ;-C(S)R o ;-(CH2) 0-4 C(O)OR o ;-(CH2) 0-4 C(O)SR o ;-(CH2) 0-4 C(O)OSiR o 3;-(CH2) 0-4 OC(O)R o ;-OC(O)(CH2) 0-4 SR-、SC(S)SR o ;-(CH2) 0-4 SC(O)R o ;-(CH2) 0-4 C(O)NR o 2;-C(S)NR o 2;-C(S)SR o ;-SC(S)SR o 、-(CH2) 0-4 OC(O)NR o 2;-C(O)N(OR o )R o ;-C(O)C(O)R o ;-C(O)CH2C(O)R o ;-C(NOR o )R o ;-(CH2) 0-4 SSR o ;-(CH2) 0-4 S(O)2R o ;-(CH2) 0-4 S(O)2OR o ;-(CH2) 0-4 OS(O)2R o ;-S(O)2NR o2; -S(O)(NR o )R o ; -S(O)2N=C(NR o 2)2;-(CH2) 0-4 S(O)R o ;-N(R o )S(O)2NR o 2;-N(R o )S(O)2R o ;-N(OR o )R o ; -C(NH)NR o 2;-P(O)2R o ;-P(O)R o 2;-OP(O)R o 2;-OP(O)(OR o )2;SiR o 3;-(C 1-4 Straight or branched alkylene)ON(R o )2; or -(C 1-4 Straight or branched alkylene)C(O)ON(R o )2.
[0045] Each R o are independently hydrogen, C 1-6 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, -CH2-(5-6 membered heteroaryl ring), or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or, notwithstanding the above definitions, R o Two independent occurrences of together with their intervening atoms form a 3-12 membered saturated, partially unsaturated or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, which may be replaced by R o A saturated carbon atom of ·o Optionally substituted with monovalent substituents independently selected from: halogen, -(CH2) 0-2 R · 、-(halogenated R · )、-(CH2) 0-2 OH, -(CH2) 0-2 OR · 、-(CH2) 0-2 CH(OR · )2; -O(halogenated R · )、-CN、-N3、-(CH2) 0-2 C(O)R · 、-(CH2)0-2 C(O)OH, -(CH2) 0-2 C(O)OR · 、-(CH2) 0-2 SR · 、-(CH2) 0-2 SH, -(CH2) 0-2 NH2, -(CH2) 0-2 NHR · 、-(CH2) 0-2 NR · 2. -NO2, -SiR · 3. -OSiR · 3. -C(O)SR · 、 -(C 1-4 Straight or branched alkylene)C(O)OR · or -SSR · .
[0046] Each R · Independently selected from C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, or a 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, and wherein each R · is unsubstituted or, if preceded by halogen, substituted only by one or more halogens; or wherein the optional substituents on the saturated carbon are divalent substituents independently selected from the following: =O, =S, =NNR * 2. =NNHC(O)R * 、=NNHC(O)OR * 、=NNHS(O)2R * , =NR * , =NOR * 、-O(C(R * 2)) 2-3 O-, or -S(C(R * 2)) 2-3 S-, or a divalent substituent attached to a vicinal substitutable carbon of an "optionally substituted" group is -O(CR * 2) 2-3 O-, where R * Each independent occurrence of is selected from hydrogen, C 1-6 Aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0047] When R* is C 1-6 When aliphatic, R * Optionally halogen, -R· 、-(halogenated R · ), -OH, -OR · 、-O(halogenated R · )、-CN、-C(O)OH、-C(O)OR · 、-NH2、-NHR · 、-NR · 2 or -NO2, where each R · Independently selected from C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, or a 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, and wherein each R · is unsubstituted or, if preceded by halogen, is substituted only by one or more halogens.
[0048] The optional substituents on the substitutable nitrogen are independently or Each of these are independently hydrogen, C 1-6 aliphatic, unsubstituted -OPh, or an unsubstituted 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or, Two independent occurrences of together with their intervening atoms form an unsubstituted 3-12 membered saturated, partially unsaturated or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; wherein when It is C 1-6 When aliphatic, Optionally halogen, -R · 、-(halogenated R · ), -OH, -OR · 、-O(halogenated R · )、-CN、-C(O)OH、-C(O)OR · 、-NH2、-NHR · 、-NR · 2 or -NO2, where each R · Independently selected from C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, or a 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, and wherein each R · is unsubstituted or, if preceded by halogen, is substituted only by one or more halogens.
[0049] The term "pharmaceutically acceptable salt" as used herein means a salt that is suitable for contact with human and lower animal tissues within the scope of reasonable medical judgment, has no undue toxicity, irritation, allergic response, etc., and is commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19 (incorporated herein by reference). Pharmaceutically acceptable salts of the compounds of the present invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts formed of an amino group with the following acids: inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid, or formed by using other methods used in the art (such as ion exchange). Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like.
[0050] In addition, acids generally considered suitable for forming pharmaceutically useful salts from basic drug compounds are discussed, for example, P. Stahl et al., Camille G. (ed.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al., Journal of Pharmaceutical Sciences (1977) 66 (1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al., The Practice of Medicinal Chemistry (1996), Academic Press, New York; and The Orange Book (Food and Drug Administration, Washington, DC on their website). These disclosures are incorporated herein by reference.
[0051] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium salts, etc. Other pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium and amine cations formed when appropriate using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates.
[0052] Unless otherwise stated, structures depicted herein are also intended to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the present invention. Unless otherwise stated, all tautomeric forms of the present compounds are within the scope of the present invention.
[0053] By methods known to those skilled in the art, for example, by chromatography and / or fractional crystallization, diastereomeric mixtures can be separated into their individual diastereomers based on their physicochemical differences. Enantiomers can be separated as follows: by reacting with an appropriate optically active compound (e.g., a chiral auxiliary, such as a chiral alcohol or Mosher's acid chloride), the enantiomer mixture is converted into a diastereomeric mixture, the diastereomers are separated, and each diastereomer is converted (e.g., hydrolyzed) into the corresponding pure enantiomer. Alternatively, a specific enantiomer of the compound of the present invention can be prepared by asymmetric synthesis. Further, in the case where the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxylic acid), a diastereomeric salt is formed with an appropriate optically active acid or base, and the diastereomers so formed are subsequently split by fractional crystallization or chromatographic methods known in the art, and the pure enantiomer is subsequently recovered.
[0054] Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates, or with all other stereoisomers or other selected stereoisomers. The chiral centers in the compounds of the invention may have the S or R configuration as defined by the IUPAC 1974 Recommendations. In addition, to the extent that the compounds described herein may exist as atropisomers (e.g., substituted biaryls), all forms of such atropisomers are considered part of the invention.
[0055] Chemical names, common names and chemical structures are used interchangeably to describe the same structure. If a chemical compound is represented by a chemical structure and a chemical name, and there is ambiguity between the structure and the name, the structure shall prevail. It should also be noted that any carbon and heteroatom with unsaturated valences in the text, schemes, examples and tables herein is assumed to have a sufficient number of hydrogen atoms to saturate the valences.
[0056] Unless otherwise indicated, the term "about" means within ±10% of the stated value. The invention encompasses embodiments wherein the value is within ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, or ±1% of the stated value.
[0057] As used herein, the terms "a" and "an" mean "one or more" and include the plural unless the context is inappropriate.
[0058] The term "alkyl" refers to a saturated straight or branched chain hydrocarbon, such as a straight or branched chain group of 1-12, 1-10 or 1-6 carbon atoms, respectively referred to herein as C1-C 12 Alkyl, C1-C 10Alkyl and C1-C6 alkyl. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, etc.
[0059] The term "cycloalkyl" refers to a monovalent saturated cyclic, bicyclic or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein as, for example, "C3-C6 cycloalkyl," which is derived from cycloalkanes. Exemplary cycloalkyl groups include cyclohexyl, cyclopentyl, cyclobutyl, and cyclopropyl. The term "cycloalkylene" refers to a divalent cycloalkyl group.
[0060] The term "haloalkyl" refers to an alkyl group substituted by at least one halogen. Exemplary haloalkyl groups include -CH2F, -CHF2, -CF3, -CH2CF3, -CF2CF3, etc. The term "haloalkylene" refers to a divalent haloalkyl group.
[0061] The terms "alkenyl" and "alkynyl" are art-recognized and refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively.
[0062] The term "alkoxyl" or "alkoxy" is well known in the art and represents an alkyl group as defined above having an oxy group attached thereto. Representative alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy, etc. The term "haloalkoxy" represents an alkoxy group substituted with at least one halogen. Exemplary haloalkoxy groups include -OCH2F, -OCHF2, -OCF3, -OCH2CF3, -OCF2CF3, etc. The term "hydroxyalkoxy" represents an alkoxy group substituted with at least one hydroxyl group. Exemplary hydroxyalkoxy groups include -OCH2CH2OH, -OCH2C(H)(OH)CH2CH2OH, etc. The term "alkyleneoxy" represents a divalent alkoxy group.
[0063] The term "oxo" is art-recognized and refers to a "=0" substituent. For example, cyclopentane substituted with an oxo group is cyclopentanone.
[0064] symbol Indicates the connection point.
[0065] When any substituent or variable occurs more than one time in any constituent or compound of the invention, its definition on each occurrence is independent of its definition at every other occurrence unless otherwise indicated.
[0066] One or more compounds of the present invention may exist in an unsolvated form as well as in a form solvated with a pharmaceutically acceptable solvent (such as water, ethanol, etc.), and the present invention is intended to encompass both solvated and unsolvated forms. "Solvate" refers to the physical association of a compound of the present invention with one or more solvent molecules. This physical association involves varying degrees of ionic bonding and covalent bonding, including hydrogen bonding. In some cases, the solvate will be able to separate, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. "Solvate" encompasses solution phases and separable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, etc. "Hydrate" is a solvate in which the solvent molecule is H2O.
[0067] As used herein, the terms "subject" and "patient" are used interchangeably and refer to an organism to be treated by the methods of the present invention. Such organisms preferably include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, etc.), and most preferably include humans.
[0068] As used herein, the term "compound" refers to an amount of a molecule sufficient to be weighed, tested for its structural characteristics, and have demonstrable utility (e.g., an amount that can be demonstrated to be active in an assay, in vitro test, or in vivo test, or an amount that can be administered to a patient and provide a therapeutic benefit).
[0069] Unless otherwise indicated, when D is specifically listed at a position or shown in a formula, the D represents a mixture of hydrogen and deuterium, wherein the amount of deuterium is about 100% (i.e., the abundance of deuterium ranges from at least 90% to 100%). In certain embodiments, the abundance of deuterium in D is from 95% to 100%, or from 97% to 100%. In certain embodiments, the abundance of deuterium in D is at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
[0070] The term "IC 50 ” is art-recognized and represents the concentration of compound required to achieve 50% inhibition of the target.
[0071] The term "effective amount" as used herein means an amount of a compound sufficient to achieve a beneficial or desired result (e.g., a therapeutic result, an improved result, an inhibitory result, or a preventive result). An effective amount can be administered in one or more administrations, applications, or dosages, and is not intended to be limited to a specific formulation or route of administration.
[0072] As used herein, the term "treat," ...
[0073] As used herein, the term "pharmaceutical composition" refers to the combination of an active agent with an inert or active carrier, making the composition particularly suitable for in vivo or ex vivo diagnostic or therapeutic use.
[0074] As used herein, the term "pharmaceutically acceptable carrier" refers to any of the standard pharmaceutical carriers, such as phosphate-buffered saline solutions, water, emulsions (e.g., such as oil / water or water / oil emulsions), and different types of wetting agents. The composition may also include stabilizers and preservatives. For examples of carriers, stabilizers, and adjuvants, see, e.g., Martin, Remington's Pharmaceutical Sciences, 15th Edition, Mack Publ. Co., Easton, PA
[1975] .
[0075] Throughout this specification, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is additionally contemplated that there are compositions of the invention that consist essentially of, or consist of, the components, and that there are processes and methods of the invention that consist essentially of, or consist of, the recited process steps.
[0076] In general, percentages of compositions specified are by weight unless otherwise indicated.
[0077] I. Deuterium-Enriched Piperidinyl-Methyl-Purinamines and Related Compounds
[0078] The present invention provides deuterium-enriched piperidinyl-methyl-purine amines and related compounds. The compounds can be used in the pharmaceutical compositions and methods of treatment described herein. The following sections describe exemplary compounds and exemplary procedures for making these compounds.
[0079] One aspect of the present invention provides a compound represented by Formula I:
[0080]
[0081] or a pharmaceutically acceptable salt thereof; wherein:
[0082] R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 are independently H or Z; and
[0083] Z is H or D, provided that the abundance of deuterium in Z is at least 75%;
[0084] The prerequisite is that R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 At least one of them is Z.
[0085] The definitions of the variables in Formula I above encompass multiple chemical groups. The present application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those described above, ii) the definition of a variable is a set of two or more chemical groups selected from those described above, and iii) a compound is defined by a combination of variables, where the variable is defined by (i) or (ii).
[0086] In certain embodiments, the compound is a compound of Formula I.
[0087] As defined generally above, R 1 is H or Z. In certain embodiments, R 1 is H. In certain embodiments, R 1 is Z. In certain embodiments, R 1 is selected from the groups depicted in the compounds in Table 1 below.
[0088] As defined generally above, R 2 is H or Z. In certain embodiments, R 2 is H. In certain embodiments, R 2 is Z. In certain embodiments, R 2 is selected from the groups depicted in the compounds in Table 1 below.
[0089] As defined generally above, R 3 is H or Z. In certain embodiments, R 3 is H. In certain embodiments, R 3 is Z. In certain embodiments, R 3 is selected from the groups depicted in the compounds in Table 1 below.
[0090] In certain embodiments, R 1 , R 2 and R 3 is H. In certain embodiments, R 1 , R 2 and R 3 It’s Z.
[0091] As defined generally above, R 4 is H or Z. In certain embodiments, R 4 is H. In certain embodiments, R 4 is Z. In certain embodiments, R 4 is selected from the groups depicted in the compounds in Table 1 below.
[0092] As defined generally above, R 5 is H or Z. In certain embodiments, R 5 is H. In certain embodiments, R 5 is Z. In certain embodiments, R 5 is selected from the groups depicted in the compounds in Table 1 below.
[0093] As defined generally above, R 6 is H or Z. In certain embodiments, R 6 is H. In certain embodiments, R 6 is Z. In certain embodiments, R 6 is selected from the groups depicted in the compounds in Table 1 below.
[0094] As defined generally above, R 7 is H or Z. In certain embodiments, R 7 is H. In certain embodiments, R 7 is Z. In certain embodiments, R7 is selected from the groups depicted in the compounds in Table 1 below.
[0095] In certain embodiments, R 4 , R 5 , R 6 and R 7 is H. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 It's H.
[0096] As defined generally above, R 8 is H or Z. In certain embodiments, R 8 is H. In certain embodiments, R 8 is Z. In certain embodiments, R 8 is selected from the groups depicted in the compounds in Table 1 below.
[0097] As defined generally above, R 9 is H or Z. In certain embodiments, R 9 is H. In certain embodiments, R 9 is Z. In certain embodiments, R 9 is selected from the groups depicted in the compounds in Table 1 below.
[0098] In certain embodiments, R 8 and R 9 is H. In certain embodiments, R 8 and R 9 is Z. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 8 and R 9 is H. In certain embodiments, R 1 , R 2 , R 3 , R 8 and R 9 It’s Z.
[0099] As defined generally above, R 10 is H or Z. In certain embodiments, R 10 is H. In certain embodiments, R 10 is Z. In certain embodiments, R 10 is selected from the groups depicted in the compounds in Table 1 below.
[0100] As defined generally above, R 11 is H or Z. In certain embodiments, R 11 is H. In certain embodiments, R 11 is Z. In certain embodiments, R 11 is selected from the groups depicted in the compounds in Table 1 below.
[0101] In certain embodiments, R 10 and R 11 is H. In certain embodiments, R 10 and R 11 is Z. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 and R 11 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 It's H.
[0102] As defined generally above, R 12 is H or Z. In certain embodiments, R 12 is H. In certain embodiments, R 12 is Z. In certain embodiments, R 12 is selected from the groups depicted in the compounds in Table 1 below.
[0103] As defined generally above, R 13 is H or Z. In certain embodiments, R 13 is H. In certain embodiments, R 13 is Z. In certain embodiments, R 13 is selected from the groups depicted in the compounds in Table 1 below.
[0104] In certain embodiments, R 12 and R 13 is H. In certain embodiments, R 12 and R 13 is Z. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 and R13 is H. In certain embodiments, R 1 , R 2 , R 3 , R 8 , R 9 , R 12 and R 13 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 12 and R 13 is Z. In certain embodiments, R 8 , R 9 , R 12 and R 13 It’s Z.
[0105] As defined generally above, R 14 is H or Z. In certain embodiments, R 14 is H. In certain embodiments, R 14 is Z. In certain embodiments, R 14 is selected from the groups depicted in the compounds in Table 1 below.
[0106] As defined generally above, R 15 is H or Z. In certain embodiments, R 15 is H. In certain embodiments, R 15 is Z. In certain embodiments, R 15 is selected from the groups depicted in the compounds in Table 1 below.
[0107] As defined generally above, R 16 is H or Z. In certain embodiments, R 16 is H. In certain embodiments, R 16 is Z. In certain embodiments, R 16 is selected from the groups depicted in the compounds in Table 1 below.
[0108] As defined generally above, R 17 is H or Z. In certain embodiments, R 17 is H. In certain embodiments, R 17 is Z. In certain embodiments, R 17 is selected from the groups depicted in the compounds in Table 1 below.
[0109] In certain embodiments, R 14 , R 15 , R 16 and R 17 is H. In certain embodiments, R 4, R 5 , R 6 , R 7 , R 10 , R 11 , R 14 , R 15 , R 16 and R 17 It's H.
[0110] As defined generally above, R 18 is H or Z. In certain embodiments, R 18 is H. In certain embodiments, R 18 is Z. In certain embodiments, R 18 is selected from the groups depicted in the compounds in Table 1 below.
[0111] As defined generally above, R 19 is H or Z. In certain embodiments, R 19 is H. In certain embodiments, R 19 is Z. In certain embodiments, R 19 is selected from the groups depicted in the compounds in Table 1 below.
[0112] In certain embodiments, R 18 and R 19 is H. In certain embodiments, R 12 , R 13 , R 18 and R 19 is H. In certain embodiments, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 It's H.
[0113] In certain embodiments, R 18 and R 19is Z. In certain embodiments, R 12 , R 13 , R 18 and R 19 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 12 , R 13 , R 18 and R 19 is Z. In certain embodiments, R 8 , R 9 , R 12 , R 13 , R 18 and R 19 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 8 , R 9 , R 12 , R 13 , R 18 and R 19 It’s Z.
[0114] As defined generally above, R 20 is H or Z. In certain embodiments, R 20 is H. In certain embodiments, R 20 is Z. In certain embodiments, R 20 is selected from the groups depicted in the compounds in Table 1 below.
[0115] In certain embodiments, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 14 , R 15 , R 16 , R 17 and R 20 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 It's H.
[0116] In certain embodiments, R 12 , R 13 , R 18 , R 19 and R 20 is Z. In certain embodiments, R 1 , R 2 , R 3 and R 20 is Z. In certain embodiments, R 8 , R 9 and R 20 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 12 , R 13 , R 18 , R 19 and R 20 is Z. In certain embodiments, R 8 , R 9 , R 12 , R 13 , R 18 , R 19 and R 20 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 8 , R 9 , R 12 , R 13 , R 18 , R 19 and R 20 It’s Z.
[0117] As defined generally above, R 21 is H or Z. In certain embodiments, R 21 is H. In certain embodiments, R 21 is Z. In certain embodiments, R 21 is selected from the groups depicted in the compounds in Table 1 below.
[0118] In certain embodiments, R12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 14 , R 15 , R 16 , R 17 and R 21 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 It's H.
[0119] In certain embodiments, R 20 and R 21 is Z. In certain embodiments, R 12 , R 13 , R 18 , R 19 and R 21 is Z. In certain embodiments, R 1 , R 2 , R 3 and R 21 is Z. In certain embodiments, R 8 , R 9 and R 21 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 12 , R 13 , R 18 , R 19 and R 21 is Z. In certain embodiments, R8 , R 9 , R 12 , R 13 , R 18 , R 19 and R 21 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 8 , R 9 , R 12 , R 13 , R 18 , R 19 and R 21 It’s Z.
[0120] As generally defined above, Z is hydrogen or deuterium, with the proviso that the abundance of deuterium in Z is at least 75%. In certain embodiments, the abundance of deuterium in Z is at least 80%. In certain embodiments, the abundance of deuterium in Z is at least 85%. In certain embodiments, the abundance of deuterium in Z is at least 90%. In certain embodiments, the abundance of deuterium in Z is at least 95%. In certain embodiments, the abundance of deuterium in Z is at least 97%. In certain embodiments, the abundance of deuterium in Z is at least 99%. In certain embodiments, the abundance of deuterium in Z is about 100%.
[0121] As defined generally above, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 In certain embodiments, at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 One of is Z. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 At least two of are Z. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 In certain embodiments, two of R are Z. 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 At least three of are Z. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 In certain embodiments, three of R are Z. 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 Four or five of are Z. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 More than five of them are Z.
[0122] In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 One or more of is Z in the position of D depicted in the compounds in Table 1 below.
[0123] In certain embodiments, the compound has an enantiomeric excess of at least 85%. In certain embodiments, the compound has an enantiomeric excess of at least 90%. In certain embodiments, the compound has an enantiomeric excess of at least 95%. In certain embodiments, the compound has an enantiomeric excess of at least 98%.
[0124] In certain embodiments, the compounds have a diastereomeric ratio of at least 10: 1. In certain embodiments, the compounds have a diastereomeric ratio of at least 15: 1. In certain embodiments, the compounds have a diastereomeric ratio of at least 20: 1. In certain embodiments, the compounds have a diastereomeric ratio of at least 50: 1. In certain embodiments, the compounds have a diastereomeric ratio of at least 100: 1.
[0125] The above description describes several embodiments associated with the compounds of formula I. All combinations of the described embodiments are specifically contemplated by this patent application.
[0126] Another aspect of the present invention provides a compound represented by Formula IA:
[0127]
[0128] or a pharmaceutically acceptable salt thereof; wherein:
[0129] R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 are independently H or Z; and
[0130] Z is H or D, provided that the abundance of deuterium in Z is at least 75%;
[0131] The prerequisite is that R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 At least one of them is Z.
[0132] The definitions of the variables in Formula IA above encompass a plurality of chemical groups. The present application contemplates embodiments in which, for example, i) the definition of a variable is a single chemical group selected from those described above, ii) the definition of a variable is a collection of two or more chemical groups selected from those described above, and iii) a compound is defined by a combination of variables, wherein the variable is defined by (i) or (ii).
[0133] In certain embodiments, the compound is a compound of Formula IA.
[0134] As defined generally above, R 1 is H or Z. In certain embodiments, R 1 is H. In certain embodiments, R 1 It’s Z.
[0135] As defined generally above, R 2 is H or Z. In certain embodiments, R 2 is H. In certain embodiments, R 2 It’s Z.
[0136] As defined generally above, R 3 is H or Z. In certain embodiments, R 3 is H. In certain embodiments, R 3 It’s Z.
[0137] In certain embodiments, R 1 , R 2 and R 3 is H. In certain embodiments, R 1 , R 2 and R 3 It’s Z.
[0138] As defined generally above, R 4 is H or Z. In certain embodiments, R 4 is H. In certain embodiments, R 4 It’s Z.
[0139] As defined generally above, R 5 is H or Z. In certain embodiments, R 5 is H. In certain embodiments, R 5 It’s Z.
[0140] As defined generally above, R 6 is H or Z. In certain embodiments, R 6 is H. In certain embodiments, R 6 It’s Z.
[0141] As defined generally above, R 7 is H or Z. In certain embodiments, R 7 is H. In certain embodiments, R 7 It’s Z.
[0142] In certain embodiments, R 4 , R 5 , R 6and R 7 is H. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 It's H.
[0143] As defined generally above, R 8 is H or Z. In certain embodiments, R 8 is H. In certain embodiments, R 8 It’s Z.
[0144] As defined generally above, R 9 is H or Z. In certain embodiments, R 9 is H. In certain embodiments, R 9 It’s Z.
[0145] In certain embodiments, R 8 and R 9 is H. In certain embodiments, R 8 and R 9 is Z. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 8 and R 9 is H. In certain embodiments, R 1 , R 2 , R 3 , R 8 and R 9 It’s Z.
[0146] As defined generally above, R 10 is H or Z. In certain embodiments, R 10 is H. In certain embodiments, R 10 It’s Z.
[0147] As defined generally above, R 11 is H or Z. In certain embodiments, R 11 is H. In certain embodiments, R 11 It’s Z.
[0148] In certain embodiments, R 10 and R 11 is H. In certain embodiments, R 10 and R 11 is Z. In certain embodiments, R 4 , R 5, R 6 , R 7 , R 10 and R 11 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 It's H.
[0149] As defined generally above, R 12 is H or Z. In certain embodiments, R 12 is H. In certain embodiments, R 12 It’s Z.
[0150] As defined generally above, R 13 is H or Z. In certain embodiments, R 13 is H. In certain embodiments, R 13 It’s Z.
[0151] In certain embodiments, R 12 and R 13 is H. In certain embodiments, R 12 and R 13 is Z. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 and R 13 is H. In certain embodiments, R 1 , R 2 , R 3 , R 8 , R 9 , R 12 and R 13 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 12 and R 13 is Z. In certain embodiments, R 8 , R 9 , R 12 and R 13 It’s Z.
[0152] As defined generally above, R 14 is H or Z. In certain embodiments, R 14is H. In certain embodiments, R 14 It’s Z.
[0153] As defined generally above, R 15 is H or Z. In certain embodiments, R 15 is H. In certain embodiments, R 15 It’s Z.
[0154] As defined generally above, R 16 is H or Z. In certain embodiments, R 16 is H. In certain embodiments, R 16 It’s Z.
[0155] As defined generally above, R 17 is H or Z. In certain embodiments, R 17 is H. In certain embodiments, R 17 It’s Z.
[0156] In certain embodiments, R 14 , R 15 , R 16 and R 17 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 14 , R 15 , R 16 and R 17 It's H.
[0157] As defined generally above, R 18 is H or Z. In certain embodiments, R 18 is H. In certain embodiments, R 18 is Z. In certain embodiments, R 18 is selected from the groups depicted in the compounds in Table 1 below.
[0158] As defined generally above, R 19 is H or Z. In certain embodiments, R 19 is H. In certain embodiments, R 19 It’s Z.
[0159] In certain embodiments, R 18 and R 19 is H. In certain embodiments, R 12 , R 13 , R 18 and R 19is H. In certain embodiments, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 It's H.
[0160] In certain embodiments, R 18 and R 19 is Z. In certain embodiments, R 12 , R 13 , R 18 and R 19 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 12 , R 13 , R 18 and R 19 is Z. In certain embodiments, R 8 , R 9 , R 12 , R 13 , R 18 and R 19 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 8 , R 9 , R 12 , R 13 , R 18 and R 19 It’s Z.
[0161] As defined generally above, R 20 is H or Z. In certain embodiments, R 20 is H. In certain embodiments, R 20 It’s Z.
[0162] In certain embodiments, R12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 14 , R 15 , R 16 , R 17 and R 20 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 It's H.
[0163] In certain embodiments, R 12 , R 13 , R 18 , R 19 and R 20 is Z. In certain embodiments, R 1 , R 2 , R 3 and R 20 is Z. In certain embodiments, R 8 , R 9 and R 20 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 12 , R 13 , R 18 , R 19 and R 20 is Z. In certain embodiments, R 8 , R 9 , R 12 , R 13 , R 18 , R19 and R 20 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 8 , R 9 , R 12 , R 13 , R 18 , R 19 and R 20 It’s Z.
[0164] As defined generally above, R 21 is H or Z. In certain embodiments, R 21 is H. In certain embodiments, R 21 It’s Z.
[0165] In certain embodiments, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 14 , R 15 , R 16 , R 17 and R 21 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 It's H.
[0166] In certain embodiments, R 20 and R 21 is Z. In certain embodiments, R 12, R 13 , R 18 , R 19 and R 21 is Z. In certain embodiments, R 1 , R 2 , R 3 and R 21 is Z. In certain embodiments, R 8 , R 9 and R 21 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 12 , R 13 , R 18 , R 19 and R 21 is Z. In certain embodiments, R 8 , R 9 , R 12 , R 13 , R 18 , R 19 and R 21 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 8 , R 9 , R 12 , R 13 , R 18 , R 19 and R 21 It’s Z.
[0167] As generally defined above, Z is hydrogen or deuterium, with the proviso that the abundance of deuterium in Z is at least 75%. In certain embodiments, the abundance of deuterium in Z is at least 80%. In certain embodiments, the abundance of deuterium in Z is at least 85%. In certain embodiments, the abundance of deuterium in Z is at least 90%. In certain embodiments, the abundance of deuterium in Z is at least 95%. In certain embodiments, the abundance of deuterium in Z is at least 97%. In certain embodiments, the abundance of deuterium in Z is at least 99%. In certain embodiments, the abundance of deuterium in Z is about 100%.
[0168] As defined generally above, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 In certain embodiments, at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 One of is Z. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 At least two of are Z. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 In certain embodiments, two of R are Z. 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 At least three of are Z. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 In certain embodiments, three of R are Z. 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 Four or five of are Z. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 More than five of them are Z.
[0169] In certain embodiments, the compound has an enantiomeric excess of at least 85%. In certain embodiments, the compound has an enantiomeric excess of at least 90%. In certain embodiments, the compound has an enantiomeric excess of at least 95%. In certain embodiments, the compound has an enantiomeric excess of at least 98%.
[0170] In certain embodiments, the compounds have a diastereomeric ratio of at least 10: 1. In certain embodiments, the compounds have a diastereomeric ratio of at least 15: 1. In certain embodiments, the compounds have a diastereomeric ratio of at least 20: 1. In certain embodiments, the compounds have a diastereomeric ratio of at least 50: 1. In certain embodiments, the compounds have a diastereomeric ratio of at least 100: 1.
[0171] The above description describes a number of embodiments associated with compounds of formula IA. All combinations of the described embodiments are specifically contemplated by this patent application.
[0172] Another aspect of the present invention provides a compound represented by Formula IB:
[0173]
[0174] or a pharmaceutically acceptable salt thereof; wherein:
[0175] R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 are independently H or Z; and
[0176] Z is H or D, provided that the abundance of deuterium in Z is at least 75%;
[0177] The prerequisite is that R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 At least one of them is Z.
[0178] The definitions of the variables in Formula IB above encompass a plurality of chemical groups. The present application contemplates embodiments in which, for example, i) the definition of a variable is a single chemical group selected from those described above, ii) the definition of a variable is a collection of two or more chemical groups selected from those described above, and iii) a compound is defined by a combination of variables, wherein the variable is defined by either (i) or (ii).
[0179] In certain embodiments, the compound is a compound of Formula IB.
[0180] In certain embodiments, the present invention provides compounds of Formula IB, wherein each variable is defined, individually and in combination, as described above in the description of Formula IA and described in the embodiments herein. For example, in certain embodiments, R 21 is Z. As another example, in certain embodiments, R 1 , R 2 and R 3 is Z. As another example, in certain embodiments, R 1 , R 2 and R 3 is Z; and R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 It's H.
[0181] The above description describes a number of embodiments associated with compounds of formula IB. All combinations of the described embodiments are specifically contemplated by this patent application.
[0182] Another aspect of the present invention provides a compound represented by Formula II:
[0183]
[0184] or a pharmaceutically acceptable salt thereof; wherein:
[0185] R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R20 are independently H or Z; and
[0186] Z is H or D, provided that the abundance of deuterium in Z is at least 75%.
[0187] The definition of the variables in Formula II above encompasses multiple chemical groups. The present application contemplates embodiments in which, for example, i) the definition of a variable is a single chemical group selected from those chemical groups described above, ii) the definition of a variable is a collection of two or more chemical groups selected from those described above, and iii) a compound is defined by a combination of variables, wherein the variable is defined by (i) or (ii).
[0188] In certain embodiments, the compound is a compound of Formula II.
[0189] As defined generally above, R 1 is H or Z. In certain embodiments, R 1 is H. In certain embodiments, R 1 is Z. In certain embodiments, R 1 is selected from the groups depicted in the compounds in Table 2 below.
[0190] As defined generally above, R 2 is H or Z. In certain embodiments, R 2 is H. In certain embodiments, R 2 is Z. In certain embodiments, R 2 is selected from the groups depicted in the compounds in Table 2 below.
[0191] As defined generally above, R 3 is H or Z. In certain embodiments, R 3 is H. In certain embodiments, R 3 is Z. In certain embodiments, R 3 is selected from the groups depicted in the compounds in Table 2 below.
[0192] In certain embodiments, R 1 , R 2 and R 3 is H. In certain embodiments, R 1 , R 2 and R 3 It’s Z.
[0193] As defined generally above, R 4 is H or Z. In certain embodiments, R 4 is H. In certain embodiments, R 4 is Z. In certain embodiments, R 4is selected from the groups depicted in the compounds in Table 2 below.
[0194] As defined generally above, R 5 is H or Z. In certain embodiments, R 5 is H. In certain embodiments, R 5 is Z. In certain embodiments, R 5 is selected from the groups depicted in the compounds in Table 2 below.
[0195] As defined generally above, R 6 is H or Z. In certain embodiments, R 6 is H. In certain embodiments, R 6 is Z. In certain embodiments, R 6 is selected from the groups depicted in the compounds in Table 2 below.
[0196] As defined generally above, R 7 is H or Z. In certain embodiments, R 7 is H. In certain embodiments, R 7 is Z. In certain embodiments, R 7 is selected from the groups depicted in the compounds in Table 2 below.
[0197] In certain embodiments, R 4 , R 5 , R 6 and R 7 is H. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 It's H.
[0198] As defined generally above, R 8 is H or Z. In certain embodiments, R 8 is H. In certain embodiments, R 8 is Z. In certain embodiments, R 8 is selected from the groups depicted in the compounds in Table 2 below.
[0199] As defined generally above, R 9 is H or Z. In certain embodiments, R 9 is H. In certain embodiments, R 9 is Z. In certain embodiments, R 9 is selected from the groups depicted in the compounds in Table 2 below.
[0200] In certain embodiments, R 8 and R 9 is H. In certain embodiments, R 8 and R 9 is Z. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 8 and R 9 is H. In certain embodiments, R 1 , R 2 , R 3 , R 8 and R 9 It’s Z.
[0201] As defined generally above, R 10 is H or Z. In certain embodiments, R 10 is H. In certain embodiments, R 10 is Z. In certain embodiments, R 10 is selected from the groups depicted in the compounds in Table 2 below.
[0202] As defined generally above, R 11 is H or Z. In certain embodiments, R 11 is H. In certain embodiments, R 11 is Z. In certain embodiments, R 11 is selected from the groups depicted in the compounds in Table 2 below.
[0203] In certain embodiments, R 10 and R 11 is H. In certain embodiments, R 10 and R 11 is Z. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 and R 11 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 It's H.
[0204] As defined generally above, R 12 is H or Z. In certain embodiments, R 12 is H. In certain embodiments, R12 is Z. In certain embodiments, R 12 is selected from the groups depicted in the compounds in Table 2 below.
[0205] As defined generally above, R 13 is H or Z. In certain embodiments, R 13 is H. In certain embodiments, R 13 is Z. In certain embodiments, R 13 is selected from the groups depicted in the compounds in Table 2 below.
[0206] In certain embodiments, R 12 and R 13 is H. In certain embodiments, R 12 and R 13 is Z. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 and R 13 is H. In certain embodiments, R 1 , R 2 , R 3 , R 8 , R 9 , R 12 and R 13 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 12 and R 13 is Z. In certain embodiments, R 8 , R 9 , R 12 and R 13 It’s Z.
[0207] As defined generally above, R 14 is H or Z. In certain embodiments, R 14 is H. In certain embodiments, R 14 is Z. In certain embodiments, R 14 is selected from the groups depicted in the compounds in Table 2 below.
[0208] As defined generally above, R 15 is H or Z. In certain embodiments, R 15 is H. In certain embodiments, R 15 is Z. In certain embodiments, R 15is selected from the groups depicted in the compounds in Table 2 below.
[0209] As defined generally above, R 16 is H or Z. In certain embodiments, R 16 is H. In certain embodiments, R 16 is Z. In certain embodiments, R 16 is selected from the groups depicted in the compounds in Table 2 below.
[0210] As defined generally above, R 17 is H or Z. In certain embodiments, R 17 is H. In certain embodiments, R 17 is Z. In certain embodiments, R 17 is selected from the groups depicted in the compounds in Table 2 below.
[0211] In certain embodiments, R 14 , R 15 , R 16 and R 17 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 14 , R 15 , R 16 and R 17 It's H.
[0212] As defined generally above, R 18 is H or Z. In certain embodiments, R 18 is H. In certain embodiments, R 18 is Z. In certain embodiments, R 18 is selected from the groups depicted in the compounds in Table 2 below.
[0213] As defined generally above, R 19 is H or Z. In certain embodiments, R 19 is H. In certain embodiments, R 19 is Z. In certain embodiments, R 19 is selected from the groups depicted in the compounds in Table 2 below.
[0214] In certain embodiments, R 18 and R 19 is H. In certain embodiments, R 12 , R 13 , R 18 and R19 is H. In certain embodiments, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 It's H.
[0215] In certain embodiments, R 18 and R 19 is Z. In certain embodiments, R 12 , R 13 , R 18 and R 19 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 12 , R 13 , R 18 and R 19 is Z. In certain embodiments, R 8 , R 9 , R 12 , R 13 , R 18 and R 19 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 8 , R 9 , R 12 , R 13 , R 18 and R 19 It’s Z.
[0216] As defined generally above, R 20 is H or Z. In certain embodiments, R 20 is H. In certain embodiments, R 20 is Z. In certain embodiments, R 20is selected from the groups depicted in the compounds in Table 2 below.
[0217] In certain embodiments, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 14 , R 15 , R 16 , R 17 and R 20 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 It's H.
[0218] In certain embodiments, R 12 , R 13 , R 18 , R 19 and R 20 is Z. In certain embodiments, R 1 , R 2 , R 3 and R 20 is Z. In certain embodiments, R 8 , R 9 and R 20 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 12 , R 13 , R 18 , R 19 and R 20 is Z. In certain embodiments, R 8 , R9 , R 12 , R 13 , R 18 , R 19 and R 20 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 8 , R 9 , R 12 , R 13 , R 18 , R 19 and R 20 It’s Z.
[0219] As generally defined above, Z is hydrogen or deuterium, with the proviso that the abundance of deuterium in Z is at least 75%. In certain embodiments, the abundance of deuterium in Z is at least 80%. In certain embodiments, the abundance of deuterium in Z is at least 85%. In certain embodiments, the abundance of deuterium in Z is at least 90%. In certain embodiments, the abundance of deuterium in Z is at least 95%. In certain embodiments, the abundance of deuterium in Z is at least 97%. In certain embodiments, the abundance of deuterium in Z is at least 99%. In certain embodiments, the abundance of deuterium in Z is about 100%.
[0220] In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 In certain embodiments, at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 One of is Z. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 At least two of are Z. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 In certain embodiments, two of R are Z. 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16, R 17 , R 18 , R 19 and R 20 At least three of are Z. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 In certain embodiments, three of R are Z. 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 Four or five of are Z. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R20 More than five of them are Z.
[0221] In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 One or more of is Z in the position of D depicted in the compounds in Table 2 below.
[0222] In certain embodiments, the compound has an enantiomeric excess of at least 85%. In certain embodiments, the compound has an enantiomeric excess of at least 90%. In certain embodiments, the compound has an enantiomeric excess of at least 95%. In certain embodiments, the compound has an enantiomeric excess of at least 98%.
[0223] The above description describes a number of embodiments associated with the compound of formula II. All combinations of the embodiments are specifically contemplated by this patent application.
[0224] Another aspect of the present invention provides a compound represented by Formula II-A:
[0225]
[0226] or a pharmaceutically acceptable salt thereof; wherein:
[0227] R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R17 , R 18 , R 19 and R 20 are independently H or Z; and
[0228] Z is H or D, provided that the abundance of deuterium in Z is at least 75%.
[0229] The definition of the variables in Formula II-A above encompasses multiple chemical groups. The present application contemplates embodiments in which, for example, i) the definition of the variable is a single chemical group selected from those chemical groups described above, ii) the definition of the variable is a set of two or more chemical groups selected from those described above, and iii) the compound is defined by a combination of variables, wherein the variable is defined by (i) or (ii).
[0230] In certain embodiments, the compound is a compound of Formula II-A.
[0231] As defined generally above, R 1 is H or Z. In certain embodiments, R 1 is H. In certain embodiments, R 1 It’s Z.
[0232] As defined generally above, R 2 is H or Z. In certain embodiments, R 2 is H. In certain embodiments, R 2 It’s Z.
[0233] As defined generally above, R 3 is H or Z. In certain embodiments, R 3 is H. In certain embodiments, R 3 It’s Z.
[0234] In certain embodiments, R 1 , R 2 and R 3 is H. In certain embodiments, R 1 , R 2 and R 3 It’s Z.
[0235] As defined generally above, R 4 is H or Z. In certain embodiments, R 4 is H. In certain embodiments, R 4 It’s Z.
[0236] As defined generally above, R 5 is H or Z. In certain embodiments, R 5 is H. In certain embodiments, R 5 It’s Z.
[0237] As defined generally above, R 6 is H or Z. In certain embodiments, R 6 is H. In certain embodiments, R 6 It’s Z.
[0238] As defined generally above, R 7 is H or Z. In certain embodiments, R 7 is H. In certain embodiments, R 7 It’s Z.
[0239] In certain embodiments, R 4 , R 5 , R 6 and R 7 is H. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 It's H.
[0240] As defined generally above, R 8 is H or Z. In certain embodiments, R 8 is H. In certain embodiments, R 8 It’s Z.
[0241] As defined generally above, R 9 is H or Z. In certain embodiments, R 9 is H. In certain embodiments, R 9 It’s Z.
[0242] In certain embodiments, R 8 and R 9 is H. In certain embodiments, R 8 and R 9 is Z. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 8 and R 9 is H. In certain embodiments, R 1 , R 2 , R 3 , R 8 and R 9 It’s Z.
[0243] As defined generally above, R 10 is H or Z. In certain embodiments, R10 is H. In certain embodiments, R 10 It’s Z.
[0244] As defined generally above, R 11 is H or Z. In certain embodiments, R 11 is H. In certain embodiments, R 11 It’s Z.
[0245] In certain embodiments, R 10 and R 11 is H. In certain embodiments, R 10 and R 11 is Z. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 and R 11 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 It's H.
[0246] As defined generally above, R 12 is H or Z. In certain embodiments, R 12 is H. In certain embodiments, R 12 It’s Z.
[0247] As defined generally above, R 13 is H or Z. In certain embodiments, R 13 is H. In certain embodiments, R 13 It’s Z.
[0248] In certain embodiments, R 12 and R 13 is H. In certain embodiments, R 12 and R 13 is Z. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 and R 13 is H. In certain embodiments, R 1 , R 2 , R 3 , R8 , R 9 , R 12 and R 13 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 12 and R 13 is Z. In certain embodiments, R 8 , R 9 , R 12 and R 13 It’s Z.
[0249] As defined generally above, R 14 is H or Z. In certain embodiments, R 14 is H. In certain embodiments, R 14 It’s Z.
[0250] As defined generally above, R 15 is H or Z. In certain embodiments, R 15 is H. In certain embodiments, R 15 It’s Z.
[0251] As defined generally above, R 16 is H or Z. In certain embodiments, R 16 is H. In certain embodiments, R 16 It’s Z.
[0252] As defined generally above, R 17 is H or Z. In certain embodiments, R 17 is H. In certain embodiments, R 17 It’s Z.
[0253] In certain embodiments, R 14 , R 15 , R 16 and R 17 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 14 , R 15 , R 16 and R 17 It's H.
[0254] As defined generally above, R 18 is H or Z. In certain embodiments, R 18 is H. In certain embodiments, R18 is Z. In certain embodiments, R 18 is selected from the groups depicted in the compounds in Table 1 below.
[0255] As defined generally above, R 19 is H or Z. In certain embodiments, R 19 is H. In certain embodiments, R 19 It’s Z.
[0256] In certain embodiments, R 18 and R 19 is H. In certain embodiments, R 12 , R 13 , R 18 and R 19 is H. In certain embodiments, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 It's H.
[0257] In certain embodiments, R 18 and R 19 is Z. In certain embodiments, R 12 , R 13 , R 18 and R 19 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 12 , R 13 , R 18 and R 19 is Z. In certain embodiments, R 8 , R 9 , R 12 , R 13 , R 18 and R19 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 8 , R 9 , R 12 , R 13 , R 18 and R 19 It’s Z.
[0258] As defined generally above, R 20 is H or Z. In certain embodiments, R 20 is H. In certain embodiments, R 20 It’s Z.
[0259] In certain embodiments, R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 14 , R 15 , R 16 , R 17 and R 20 is H. In certain embodiments, R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 It's H.
[0260] In certain embodiments, R 12 , R 13 , R 18 , R 19 and R 20 is Z. In certain embodiments, R 1 , R 2, R 3 and R 20 is Z. In certain embodiments, R 8 , R 9 and R 20 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 12 , R 13 , R 18 , R 19 and R 20 is Z. In certain embodiments, R 8 , R 9 , R 12 , R 13 , R 18 , R 19 and R 20 is Z. In certain embodiments, R 1 , R 2 , R 3 , R 8 , R 9 , R 12 , R 13 , R 18 , R 19 and R 20 It’s Z.
[0261] As generally defined above, Z is hydrogen or deuterium, with the proviso that the abundance of deuterium in Z is at least 75%. In certain embodiments, the abundance of deuterium in Z is at least 80%. In certain embodiments, the abundance of deuterium in Z is at least 85%. In certain embodiments, the abundance of deuterium in Z is at least 90%. In certain embodiments, the abundance of deuterium in Z is at least 95%. In certain embodiments, the abundance of deuterium in Z is at least 97%. In certain embodiments, the abundance of deuterium in Z is at least 99%. In certain embodiments, the abundance of deuterium in Z is about 100%.
[0262] In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17, R 18 , R 19 and R 20 In certain embodiments, at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 One of is Z. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 At least two of are Z. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20In certain embodiments, two of R are Z. 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 At least three of are Z. In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 In certain embodiments, three of R are Z. 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 Four or five of are Z. In certain embodiments, R 1 , R 2 , R3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 More than five of them are Z.
[0263] In certain embodiments, the compound has an enantiomeric excess of at least 85%. In certain embodiments, the compound has an enantiomeric excess of at least 90%. In certain embodiments, the compound has an enantiomeric excess of at least 95%. In certain embodiments, the compound has an enantiomeric excess of at least 98%.
[0264] The above description describes a number of embodiments associated with compounds of formula II-A. All combinations of the embodiments are specifically contemplated by this patent application.
[0265] Another aspect of the present invention provides a compound in Table 1 or 2 below or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1 or 2 below. In certain embodiments, the compound is a compound in Table 1 below or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1 below. In certain embodiments, the compound is a compound in Table 2 below or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 2 below.
[0266] Table 1.
[0267]
[0268]
[0269]
[0270]
[0271]
[0272] Table 2.
[0273]
[0274]
[0275]
[0276]
[0277]
[0278]
[0279]
[0280] Methods for preparing the compounds described herein are illustrated in the following synthetic schemes. The schemes are given for the purpose of illustrating the present invention and are not intended to limit the scope or spirit of the invention. The raw materials shown in the schemes can be obtained from commercial sources or can be prepared based on procedures described in the literature. Additional strategies for preparing raw materials and non-deuterium-enriched piperidinyl-methyl-purine amines and related compounds are described in, for example, WO 2021 / 028854, the entire contents of which are hereby incorporated by reference.
[0281] In the scheme, it will be appreciated by those skilled in the art of organic synthesis that the functional groups present on the various parts of the molecule should be compatible with the proposed reagent and reaction. Substituents incompatible with reaction conditions are apparent to those skilled in the art, and therefore alternative methods (e.g., using blocking groups or substitution reactions) are pointed out. Blocking group chemistry and strategy are well known in the art, such as in " Protecting Groups in Organic Synthesis ", TW Greene and PGM Wuts, 3rd edition, John Wiley & Sons, 1999 (whose entire content is hereby incorporated by reference) are described in detail.
[0282] The synthetic route shown in Scheme 1 is a general method for preparing deuterium-enriched piperidinyl-methyl-purine amines and related compounds H. A halophenol A (where X is a halogen such as Br or I) is subjected to methylating conditions (using, for example, a base such as K2CO3 or DIPEA, and a methylating agent B [such as commercially available iodomethane or perdeuterated iodomethane, where LG 1 is a leaving group such as iodide]), followed by metalation of the halide X (using, for example, lithium / halogen exchange, optionally followed by conversion to, for example, an organozinc, borate ester or boronic acid [using, for example, a trialkyl borate, and hydrolysis of the resulting borate]), followed by transition metal-mediated coupling with a pyridine C (where LG 2 is a leaving group such as bromide, iodide, or sulfonate; LG 3is a leaving group such as fluoride, chloride or sulfonate; and R is a suitable group such as methyl, ethyl or benzyl) to provide an arylated pyridine ester D. The piperidine E (where R A It is -C(OH)(R 21 )-C(R 20 )F2 or -C(O)-C(R 20 )F2 and PG 1 Condensation of a pyridine D (using, for example, nucleophilic aromatic substitution conditions with a base such as K2CO3 or DIPEA in a polar aprotic solvent such as DMSO) followed by reduction of the ester group (using, for example, a metal hydride such as LiAlH4, or a metal deuteride such as commercially available LiAlD4) provides a hydroxymethyl pyridine F. Activation of the hydroxyl group of pyridine F, either in a separate step (e.g., activation to a sulfonate ester using, for example, tosyl chloride and a base such as DIPEA) or in situ (e.g., under Mitsunobu conditions), and displacement with a protected adenine G (where PG 2 is a protecting group such as Boc), followed by global deprotection (using, for example, reduction such as hydrogenolysis, provided that PG 1 and / or PG 2 At least one of is benzyl; and / or acidic conditions, such as TFA or HCl, provided that PG 1 and / or PG 2 At least one of which is Boc), provides deuterium-enriched piperidinyl-methyl-purine amines and related compounds H.
[0283] Solution 1.
[0284]
[0285] Deuterium enrichment can also be included in the piperidine intermediate E of Scheme 1, for example, as shown in Scheme 2. Subjecting piperidine-2,6-dione A (wherein PG is a protecting group such as benzyl) to hydrolysis conditions (using, for example, LiOH and H2O2 in an alcohol solvent such as EtOH), followed by a Lossen / Hofman / Curtius / Schmidt rearrangement, provides the aminopiperidine B. Reduction of the 2,6-dione (using, for example, a metal hydride such as LiAlH4 or NaBH4, a metal deuteride such as commercially available LiAlD4 or NaBD4, a borane such as BH3 or BD3, or a combination thereof), followed by deprotection (using, for example, reduction such as hydrogenolysis, provided that PG is benzyl), provides piperidine C, which can be deuterium enriched. Several examples of deuterium incorporation in piperidine-2,6-dione are provided in, for example, US 2007 / 0276001 and Perrin, CL, et al., J. Am. Chem. Soc. (2005) Vol. 127, No. 26, pp. 9641-9647.
[0286] Solution 2.
[0287]
[0288] The synthetic route shown in Scheme 3 is a method for preparing the specific piperidine-2,6-dione A of Scheme 2, including wherein R A The groups may be those that are deuterium-enriched. Aldol addition of piperidine-2,6-dione A to aldehyde B (or its equivalent, such as acetal or hemiacetal) provides alcohol C. Resolution of alcohol C (using, for example, chiral chromatography) provides a single stereoisomer D. Alternatively, oxidation of alcohol C provides ketone E. Reduction of ketone E (using, for example, a deuterium-enriched reducing agent, such as commercially available LiAlD4), followed by resolution (using, for example, chiral chromatography), provides a single stereoisomer F. Alternatively, use of a deuterium-enriched stoichiometric reducing agent (e.g., BD3 or D2) and a chiral catalyst (e.g., oxazaborilidine or ruthenium / 1,2-diphenylethane-1,2-diamine catalyst) provides a single stereoisomer F without chiral chromatography. Enantiomers and diastereomers of alcohols D and F are prepared as single stereoisomers using similar procedures. Finally, the ketone E can alternatively be deuterated via its enolate or enolate (using, for example, D2O and an acid or base catalyst) to provide the α-deuterated ketone G.
[0289] Solution 3.
[0290]
[0291] The modular synthetic pathways shown in Schemes 1, 2 and 3 can also be easily modified by those skilled in the art to provide additional deuterium-enriched piperidinyl-methyl-purine amines and related compounds as follows: functional group transformations are performed on intermediates and final compounds, such as oxidation and reduction with deuterium-enriched reagents. Such functional group transformations are well known in the art, such as described in "Comprehensive Organic Synthesis" (BMTrost and I.Fleming, ed., 1991-1992).
[0292] The compounds described herein can be provided in an isolated or purified form. An isolated or purified compound is a group of compounds that have been separated from their environment, for example, if prepared in a laboratory environment, from a crude reaction mixture, or if naturally occurring, removed from its natural environment. Examples of purity of isolated compounds include, for example, at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, to 100% (by weight).
[0293] Another aspect of the present invention provides a unit amount of a deuterium-enriched compound described herein, such as at least (a) 1 μg of a disclosed deuterium-enriched compound, (b) 1 mg or (c) 1 gram. In other embodiments, the amount is, for example, at least 0.01, 0.02, 0.03, 0.04, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5 or 1 mole of compound. This amount also encompasses laboratory scale (e.g., gram scale, including 1, 2, 3, 4, 5g, etc.), kilogram laboratory scale (e.g., kilogram scale, including 1, 2, 3, 4, 5kg, etc.) and industrial or commercial scale (e.g., multi-kilogram or more scale, including 100, 200, 300, 400, 500kg, etc.) amounts, because these will be more useful in actual drug manufacturing. Industrial / commercial scale refers to the amount of a product produced in a batch designed for clinical trials, formulations, sales / distribution to the public, etc.
[0294] II. Therapeutic Uses of Deuterium-Enriched Piperidinyl-Methyl-Purinamines and Related Compounds
[0295] Deuterium-enriched piperidinyl-methyl-purine amines and related compounds described herein (such as compounds of Formula I or II) or other compounds in Section I provide therapeutic benefits to subjects suffering from cancer and other diseases or conditions. Thus, one aspect of the invention provides a method for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2). The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound described herein (such as a compound of Formula I or II) to treat the disease or condition. In certain embodiments, the compound is a compound of Formula I or II as defined in one of the above embodiments.
[0296] Examples of diseases or conditions mediated by NSD2 include, but are not limited to, breast cancer, cervical cancer, skin cancer (particularly squamous cell carcinoma of the skin), ovarian cancer, gastric cancer, prostate cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, head and neck cancer, peripheral nerve sheath tumors, osteosarcoma, multiple myeloma, neuroblastoma, leukemia (particularly acute lymphoblastic leukemia), non-Hodgkin's lymphoma (particularly mantle cell lymphoma), and pulmonary hypertension.
[0297] In certain embodiments, the disease or condition mediated by NSD2 is cancer.
[0298] In certain embodiments, the disease or condition mediated by NSD2 is selected from solid tumors, leukemia, myeloma, lymphoma and hypertension. In certain embodiments, the disease or condition mediated by NSD2 is a solid tumor. In certain embodiments, the disease or condition mediated by NSD2 is selected from leukemia, myeloma and lymphoma. In certain embodiments, the disease or condition mediated by NSD2 is leukemia. In certain embodiments, the disease or condition mediated by NSD2 is myeloma. In certain embodiments, the disease or condition mediated by NSD2 is lymphoma. In certain embodiments, the disease or condition mediated by NSD2 is hypertension.
[0299] In certain embodiments, the disease or condition mediated by NSD2 is breast cancer, cervical cancer, skin cancer, ovarian cancer, gastric cancer, prostate cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, head and neck cancer, peripheral nerve sheath tumors, osteosarcoma, multiple myeloma, neuroblastoma, leukemia, non-Hodgkin's lymphoma, or pulmonary hypertension. In certain embodiments, the disease or condition mediated by NSD2 is breast cancer. In certain embodiments, the disease or condition mediated by NSD2 is cervical cancer. In certain embodiments, the disease or condition mediated by NSD2 is ovarian cancer. In certain embodiments, the disease or condition mediated by NSD2 is gastric cancer. In certain embodiments, the disease or condition mediated by NSD2 is prostate cancer. In certain embodiments, the disease or condition mediated by NSD2 is pancreatic cancer. In certain embodiments, the disease or condition mediated by NSD2 is hepatocellular carcinoma. In certain embodiments, the disease or condition mediated by NSD2 is head and neck cancer. In certain embodiments, the disease or condition mediated by NSD2 is peripheral nerve sheath tumor. In certain embodiments, the disease or condition mediated by NSD2 is osteosarcoma. In certain embodiments, the disease or condition mediated by NSD2 is multiple myeloma. In certain embodiments, the disease or condition mediated by NSD2 is neuroblastoma. In certain embodiments, the disease or condition mediated by NSD2 is pulmonary hypertension.
[0300] In certain embodiments, the disease or condition mediated by NSD2 is acute lymphoblastic leukemia, squamous cell carcinoma of the skin, or mantle cell lymphoma. In certain embodiments, the disease or condition mediated by NSD2 is acute lymphoblastic leukemia. In certain embodiments, the disease or condition mediated by NSD2 is squamous cell carcinoma of the skin. In certain embodiments, the disease or condition mediated by NSD2 is mantle cell lymphoma.
[0301] In certain embodiments, the disease or condition mediated by NSD2 is lung cancer. In certain embodiments, the disease or condition mediated by NSD2 is small cell or non-small cell lung cancer. In certain embodiments, the disease or condition mediated by NSD2 is small cell lung cancer. In certain embodiments, the disease or condition mediated by NSD2 is non-small cell lung cancer.
[0302] In certain embodiments, the disease or condition mediated by NSD2 is leukemia. In certain embodiments, the disease or condition mediated by NSD2 is acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML) or chronic myelomonocytic leukemia (CMML). In certain embodiments, the disease or condition mediated by NSD2 is AML. In certain embodiments, the disease or condition mediated by NSD2 is CML. In certain embodiments, the disease or condition mediated by NSD2 is CMML.
[0303] In certain embodiments, the disease or condition mediated by NSD2 is skin cancer. In certain embodiments, the disease or condition mediated by NSD2 is melanoma, basal cell carcinoma, or squamous cell carcinoma. In certain embodiments, the disease or condition mediated by NSD2 is melanoma. In certain embodiments, the disease or condition mediated by NSD2 is basal cell carcinoma.
[0304] In certain embodiments, the disease or condition mediated by NSD2 is lymphoma. In certain embodiments, the disease or condition mediated by NSD2 is Hodgkin's lymphoma or non-Hodgkin's lymphoma. In certain embodiments, the disease or condition mediated by NSD2 is Hodgkin's lymphoma. In certain embodiments, the disease or condition mediated by NSD2 is non-Hodgkin's lymphoma. In certain embodiments, the disease or condition mediated by NSD2 is mantle cell lymphoma or diffuse large B-cell lymphoma. In certain embodiments, the disease or condition mediated by NSD2 is diffuse large B-cell lymphoma.
[0305] In certain embodiments, the disease or condition mediated by NSD2 is myeloma.
[0306] In certain embodiments, the disease or condition mediated by NSD2 is thyroid cancer. In certain embodiments, the disease or condition mediated by NSD2 is colon cancer.
[0307] In certain embodiments, the cancer overexpresses NSD2. In certain embodiments, the cancer has a mutation in NSD2. In certain embodiments, the cancer has an activating mutation in NSD2. In certain embodiments, the cancer has a t(4;14)(p16.3;q32.3) translocation in NSD2. In certain embodiments, the cancer has an E1099K mutation in NSD2. In certain embodiments, the cancer has a T1150A mutation in NSD2.
[0308] In certain embodiments, the subject is a human. In certain embodiments, the subject is an adult. In certain embodiments, the subject is a child. In certain embodiments, the subject is an elderly.
[0309] Another aspect of the invention provides the use of a compound described herein (such as a compound of Formula I or II, or other compounds in Section I) in the preparation of a medicament. In certain embodiments, the medicament is used to treat a disease or condition described herein, such as cancer.
[0310] Another aspect of the invention provides the use of a compound described herein (such as a compound of Formula I or II, or other compounds in Section I) for treating a disease or condition such as a disease or condition described herein (eg, cancer).
[0311] In addition, the compounds described herein (such as compounds of Formula I or II) or other compounds in Section I inhibit the activity of nuclear SET domain-containing protein 2 (NSD2). Therefore, another aspect of the present invention provides a method of inhibiting the activity of nuclear SET domain-containing protein 2 (NSD2). The method comprises contacting NSD2 with an effective amount of deuterium-enriched piperidinyl-methyl-purine amine or related compounds described herein (such as compounds of Formula I or II) or other compounds in Section I to inhibit the activity of NSD2. In certain embodiments, the compound is a compound of Formula I or II as defined in one of the above embodiments.
[0312] Compounds can be tested for their ability to bind and / or inhibit NSD2 activity according to any of a variety of assays known in the art, including, for example, LC-MS / MS enzyme assays to monitor SAH production, cellular FRET assays, cellular ELISA assays, methyltransferase enzymatic luminescence assays to monitor SAH production, and radiometric assays using tritium-labeled SAMs. Such assays are described, for example, in WO 2021 / 028854 and Coussens, NP et al. J. Biol. Chem. (2018) Vol. 293, No. 35, pp. 13750-13755; the entire contents of each of which are hereby incorporated by reference.
[0313] The benefits of the deuterium-enriched compounds described herein may include increased metabolic stability. Such increased metabolic stability may result in a longer half-life of the deuterium-enriched compounds in the patient's circulatory system and / or a higher Cmax value in the patient's plasma. The longer half-life of the deuterium-enriched compounds may allow the deuterium-enriched compounds to be administered to the patient at a lower frequency while still reaching a desirable level of efficacy. The higher Cmax values of the deuterium-enriched compounds may provide greater efficacy in the treatment of diseases using the deuterium-enriched compounds. The increased metabolic stability of the compounds may also allow the administration of lower doses of compounds to the patient--such lower doses of compounds may reduce the frequency and / or intensity of any adverse side effects.
[0314] The metabolic stability of the compound of deuterium enrichment can be evaluated using the program of the metabolic stability of the measurement compound described in the literature.For example, the compound of deuterium enrichment to be tested can be incubated at 37°C in a solution containing the hepatocyte obtained from a subject (for example, mouse, rat, dog, monkey or people).Aliquots of the solution are obtained at several time points (for example, 0, 15, 30, 60, 120 and 180 minutes), and aliquots are evaluated by analytical methods (for example, HPLC and / or HPLC-MS technology) to determine the amount of the compound of original deuterium enrichment and / or the presence of any metabolites and / or degradation products of the compound of original deuterium enrichment. Reference substances (for example, verapamil) can be used as internal standards during the experiment.
[0315] In a more specific embodiment, the metabolic stability of deuterium-enriched compounds can be evaluated by the following procedure: (i) preparing an appropriate substrate (e.g., nucleosomes) for a particular methyltransferase (e.g., NSD2) in a freshly prepared reaction buffer, (ii) delivering the appropriate methyltransferase to the substrate solution and gently mixing, (iii) delivering deuterium-enriched test compounds in DMSO to the methyltransferase reaction mixture in the nanoliter range by using, for example, acoustic technology (Echo 550, LabCyte Inc. Sunnyvale, CA) and incubating at room temperature for 20 min, (iv) adding 1 μM of 3 H-SAM (methyl donor) was delivered to the reaction mixture to initiate the reaction, (v) the reaction mixture was incubated at 30°C for 1 hour, (vi) the reaction mixture was delivered onto filter paper for detection, and (vii) the data were analyzed using Excel and GraphPad Prism software.
[0316] III. Combination Therapy
[0317] Another aspect of the invention provides combination therapy. Deuterium-enriched piperidinyl-methyl-purine amine or related compounds described herein (e.g., compounds of Formula I or II, or other compounds in Section I) or pharmaceutically acceptable salts thereof can be used in combination with another therapeutic agent to treat a disease or condition, such as cancer.
[0318] Thus, in certain embodiments, the present invention provides a method of treating a disclosed disease or condition, comprising administering to a patient in need thereof an effective amount of a compound disclosed herein and co-administering simultaneously or sequentially an effective amount of one or more additional therapeutic agents, such as those described herein. In certain embodiments, the method comprises co-administering one additional therapeutic agent. In certain embodiments, the method comprises co-administering two additional therapeutic agents.
[0319] One or more other therapeutic agents can be administered separately from the compounds or compositions of the present invention as part of a multiple dosage regimen. Alternatively, one or more other therapeutic agents can be part of a single dosage form, mixed with the compounds of the present invention in a single composition. If administered as a multiple dosage regimen, one or more other therapeutic agents and the compounds or compositions of the present invention can be administered simultaneously, sequentially, or within a period of time of each other.
[0320] In certain embodiments, the additional therapeutic agent is an anticancer agent, an antiallergic agent, an antinausea agent (or antiemetic), a pain reliever, a cytoprotective agent, or a combination thereof. In certain embodiments, the additional therapeutic agent is an anticancer agent, an analgesic, an anti-inflammatory agent, or a combination thereof.
[0321] In certain embodiments, the additional therapeutic agent is an anticancer agent or a chemotherapeutic agent. The examples of anticancer agents contemplated for use in the combination therapy of the present invention include, but are not limited to, erlotinib, bortezomib, fulvestrant, sunitinib (sunitib), imatinib mesylate, letrozole, finasunate, platinums such as oxaliplatin, carboplatin and cisplatin, finasunate, fluorouracil, rapamycin, folinic acid, lapatinib, lonafarnib, sorafenib, gefitinib, camptothecin, topotecan, bryostatin, adolesin, anthracyclines, kazeresin, biszeletin, dolastatin, auristatin, duocarmycin, soft coral alcohol, taxols such as paclitaxel or docetaxel, cyclophosphamide, doxorubicin, vincristine alkali, prednisone or prednisolone, other alkylating agents such as dichloromethane, chlorambucil and ifosfamide, antimetabolites such as azathioprine or mercaptopurine, other microtubule inhibitors (vinca alkaloids such as vincristine, vinblastine, vinorelbine and vindesine, and taxanes), podophyllotoxins (etoposide, teniposide, etoposide phosphate and epipodophyllotoxins), topoisomerase inhibitors, other cytotoxins such as actinomycin, daunorubicin, valrubicin, idarubicin, edracolizumab, epirubicin, bleomycin, plicamycin, mitomycin, and other anticancer antibodies (cetuximab, bevacizumab, ibritumomab, abamectin, Vortumab, adelimumab, atezolizumab, alacizumab, alemtuzumab, mammotumomab, apolizumab, baviximab, belimumab, bivacizumab maytansine, rantumomab, vebutuximab, mecanizumab, catumazomab, cetuximab, pocitaluzumab, citumumab, titan-clituzumab, canatumumab, daclizumab, daclizumab, demetonumab, emtansomumab, edrazolizumab, evolozumab, epratuzumab, ermasomumab, edazumab, farizumab, fentolimumab, fusumumab, galiximab, vetin-glentumumab, gemtuzumab anti-cancer drugs, ibritumomab tiuxetan, inotuzumab, intumumab, ipilimumab, itumumab, labetuzumab, lexatumumab, lintuzumab, rucamumab, lumilisimab, mapatumumab, matuzumab, milatuzumab, mitumumab, tanacol, tanatumomab, necimumab, nimotuzumab, ofatumumab, olaratumab, motulumab, orgovoumab, pantumumab, pemtumomab, pertuzumab, pintuzumab, plimumab, ramucirumab, rituximab, rotuximab, rituximab, sirolimus, tacatuzumab tetraxetan, patamumomab, tetumomab, tesimumab, tegazumab, tositumomab, or 131I-tositumomab, trastuzumab, tremelimumab, simoleukin-1, veltuzumab, visilizumab, volocixumab, futumomab, zalumab, zalumab, IGN-101, MDX-010, ABX-EGR, EMD72000, ior-t1, MDX-220, MRA, H-11scFv, huJ591, TriGem, TriAb, R3, MT-201, G-250, ACA-125, Onyvax-105, CD:-960, Cea-Vac, BrevaRex AR54, IMC-1C11, GlioMab-H, ING-1, anti-LCG MAbs, MT-103, KSB-303, Therex, KW2871, anti-HMI.24, anti-PTHrP, 2C4 antibodies, SGN-30, TRAIL-RI MAbs, prostate cancer antibodies, H22xKi-r, ABX-Mai, Imuteran, Monopharm-C) and antibody-drug conjugates comprising any of the above agents (particularly the auristatins MMAE and MMAF, maytansines such as DM-1, calicheamicins or various cytotoxins).
[0322] In certain embodiments, the additional therapeutic agent is selected from anastrozole Bicalutamide Bleomycin sulfate Busulfan Busulfan Injection Capecitabine N4-pentyloxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin Carmustine Chlorambucil Cisplatin Cladribine Cyclophosphamide ( or ), cytosine arabinoside, cytosine arabinoside Cytarabine liposome injection Dacarbazine Dactinomycin (actinomycin D, ), daunorubicin hydrochloride Daunorubicin citrate liposome injection Dexamethasone, docetaxel Doxorubicin Hydrochloride Etoposide Fludarabine phosphate 5-Fluorouracil Flutamide Tezacitabine, gemcitabine (difluorodeoxycytidine), hydroxyurea Idabi Ifosfamide Irinotecan L-Asparaginase Calcium folinate, melphalan 6-Mercaptopurine Methotrexate Mitoxantrone Gemtuzumab ozogamicin (MYLOTARGTM), paclitaxel Albumin-bound paclitaxel Phoenix (yttrium 90 / MX-DTPA), pentostatin, polyphenylpropanone 20, and carmustine implants Tamoxifen citrate Teniposide 6-thioguanine, thiotepa, tirapazamine Topotecan Hydrochloride Injection Vinblastine Vincristine Vinorelbine
[0323] In certain embodiments, the additional therapeutic agent is capable of inhibiting BRAF, MEK, CDK4 / 6, SHP-2, HDAC, EGFR, MET, mTOR, PI3K or AKT or a combination thereof. In a specific embodiment, the compounds of the invention are combined with other therapeutic agents selected from vemurafinib, debrafinib, LGX818, trametinib, MEK162, LEE011, PD-0332991, panobinostat, verinostat, romidepsin, cetuximab, gefitinib, erlotinib, lapatinib, pantuximab, fentanib, INC280, everolimus, simolimus, BMK120, BYL719 or CLR457 or a combination thereof.
[0324] In certain embodiments, the additional therapeutic agent is selected based on the disease or condition being treated. For example, in the treatment of melanoma, the additional therapeutic agent is selected from aldesleukin (e.g., ), dabrafenib (e.g., ), dacarbazine, recombinant interferon α-2b (e.g., A), ipilimumab, trametinib (e.g., ), pegylated interferon α-2b (e.g., SYLATRONTM), Vemurafenib (e.g., )) and ipilimumab (e.g., ).
[0325] For the treatment of ovarian cancer, the additional therapeutic agent is selected from doxorubicin hydrochloride Carboplatin Cyclophosphamide Cisplatin Liposomal doxorubicin hydrochloride Gemcitabine Hydrochloride Topotecan Hydrochloride and paclitaxel
[0326] For the treatment of thyroid cancer, the additional therapeutic agent is selected from doxorubicin hydrochloride Cabozantinib-S-malate Fantanib
[0327] For the treatment of colon cancer, the additional therapeutic agent is selected from fluorouracil (e.g., ), Bevacizumab Irinotecan hydrochloride Capecitabine Cetuximab Oxaliplatin Calcium folinate Regorafenib Panitumumab Aflibercept
[0328] For the treatment of lung cancer, the additional therapeutic agent is selected from methotrexate, methotrexate LPF (e.g., FOLEX ), Paclitaxel Paclitaxel albumin-stabilized nanoparticle formulation Afatinib bismaleate Pemetrexed disodium Bevacizumab Carboplatin Cisplatin Crizotinib Erlotinib Hydrochloride Gefitinib and gemcitabine hydrochloride
[0329] For the treatment of pancreatic cancer, the other therapeutic agent may be selected from fluorouracil Erlotinib Hydrochloride Gemcitabine Hydrochloride and mitomycin or mitomycin C (MITOZYTREX™, ).
[0330] For the treatment of cervical cancer, the additional therapeutic agent is selected from bleomycin Cisplatin and topotecan hydrochloride
[0331] For the treatment of head and neck cancer, the additional therapeutic agent is selected from methotrexate, methotrexate LPF (e.g., FOLEX ), fluorouracil Bleomycin Cetuximab Cisplatin and docetaxel
[0332] For the treatment of leukemias including chronic myelomonocytic leukemia (CMML), the additional therapeutic agent is selected from bosutinib Cyclophosphamide Cytarabine Dasatinib Imatinib mesylate Ponatinib Nilotinib Homoharringtonine
[0333] In some cases, patients may develop allergic reactions to the compounds of the invention and / or other anticancer agents during or after administration. Therefore, antiallergic agents may be administered to minimize the risk of allergic reactions. Suitable antiallergic agents include corticosteroids such as dexamethasone (e.g., ), beclomethasone (e.g. ), hydrocortisone (also known as cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate; e.g., Hydrocortisone phosphate, HYDROCORT and ), prednisolone (e.g. and ), prednisone (e.g. and ), methylprednisolone (also known as 6-methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate; e.g., and ); antihistamines, such as diphenhydramine (e.g., ), hydroxyzine, and cyproheptadine; and bronchodilators, such as beta-adrenergic receptor agonists, albuterol (e.g., ) and terbutaline
[0334] In other cases, patients may experience nausea during and after administration of the compounds of the invention and / or other anticancer agents. Therefore, antiemetics may be administered to prevent nausea (epigastric) and vomiting. Suitable antiemetics include aprepitant Ondansetron Granisetron Hydrochloride Lorazepam ( Dexamethasone Prochlorperazine Cassopitant and ) and their combinations.
[0335] In other cases, medications are prescribed to relieve pain felt during treatment and make the patient feel more comfortable. Common over-the-counter pain relievers such as Opioid analgesics such as hydrocodone / acetaminophen or hydrocodone / acetaminophen (e.g. ), morphine (e.g. or ), oxycodone (e.g., or ), Oxymorphone Hydrochloride and fentanyl (e.g., ) can also be used for moderate or severe pain.
[0336] In addition, cytoprotectants (such as neuroprotectants, free radical scavengers, cardioprotectants, anthracycline extravasation neutralizers, nutrients, etc.) can be used as adjunctive therapy to protect normal cells from treatment toxicity and limit organ toxicity. Suitable cytoprotectants include amifostine Glutamine, Dimethoate Mesna Dexrazoxane ( or ), Zali Roden and folinic acid (also known as folinic acid, folinic acid, and folinic acid).
[0337] In yet another aspect, the compounds of the invention can be used in conjunction with known therapeutic procedures, for example, with the administration of hormones or in radiation therapy. In certain cases, the compounds of the invention can be used as radiosensitizers, particularly for the treatment of tumors that exhibit poor sensitivity to radiation therapy.
[0338] The dosage and dosage regimen of the active ingredient used in the combination therapy can be determined by the attending clinician. In certain embodiments, the compound described herein (e.g., a compound of Formula I or II, or other compounds in Part I) and another therapeutic agent are administered at a dosage that is usually used when such an agent is used as a monotherapy for treating the disease or condition. In other embodiments, the dosage of the compound described herein (e.g., a compound of Formula I or II, or other compounds in Part I) and another therapeutic agent is lower than the dosage that is usually used when such an agent is used as a monotherapy for treating the disease or condition. In certain embodiments, the compound described herein (e.g., a compound of Formula I or II, or other compounds in Part I) and another therapeutic agent are present in the same composition, which is suitable for oral administration.
[0339] In certain embodiments, the compounds described herein (e.g., compounds of Formula I or II, or other compounds in Section I) and the additional therapeutic agent may act additively or synergistically. Synergistic combinations may allow the use of lower doses of one or more agents and / or less frequent administration of one or more agents of the combination therapy. Lower doses or less frequent administration of one or more agents may reduce the toxicity of the treatment without reducing the efficacy of the treatment.
[0340] Another aspect of the invention is a kit comprising a therapeutically effective amount of a compound described herein (e.g., a compound of Formula I or II, or other compounds in Section I), a pharmaceutically acceptable carrier, vehicle or diluent, and optionally at least one additional therapeutic agent listed above. In certain embodiments, the kit further comprises instructions, such as instructions for treating a disease described herein.
[0341] IV. Pharmaceutical Composition and Dosing Considerations
[0342] As noted above, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of one or more of the compounds described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and / or diluents. The pharmaceutical compositions can be specifically formulated for administration in solid or liquid form, including those suitable for: (1) oral administration, e.g., drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those for buccal, sublingual and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, e.g., by subcutaneous, intramuscular, intravenous or epidural injection, e.g., as a sterile solution or suspension, or a sustained release formulation; (3) topical application, e.g., as a cream, ointment, or a controlled release patch or spray applied to the skin; (4) intravaginally or intrarectally, e.g., as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8) nasally. In certain embodiments, the present invention provides a pharmaceutical composition comprising a compound described herein (eg, a compound of Formula I or II) and a pharmaceutically acceptable carrier.
[0343] As used herein, the phrase "therapeutically effective amount" refers to an amount of a compound, material, or composition comprising a compound of the invention that is effective to produce some desired therapeutic effect in at least one subpopulation of cells in an animal at a reasonable benefit / risk ratio applicable to any medical treatment.
[0344] The phrase "pharmaceutically acceptable" is used herein to refer to compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0345] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition.
[0346] Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, etc.; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, etc.; and (3) metal chelators, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, etc.
[0347] The preparations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and / or parenteral administration. The preparations can be conveniently presented in unit dosage form and can be prepared by any method well known in the pharmaceutical field. The amount of active ingredients that can be combined with carrier materials to produce a single dosage form will vary with the host being treated, the specific mode of administration. The amount of active ingredients that can be combined with carrier materials to produce a single dosage form is generally the amount of the compound that produces the therapeutic effect. Typically, in one hundred percent, the amount ranges from about 0.1% to about 99% of the active ingredient, preferably from about 5% to about 70%, and most preferably from about 10% to about 30%.
[0348] In certain embodiments, the formulations of the present invention comprise excipients selected from cyclodextrins, cellulose, liposomes, micelle formers (e.g., bile acids) and polymer carriers (e.g., polyesters and polyanhydrides); and compounds of the present invention. In certain embodiments, the aforementioned formulations allow the compounds of the present invention to have oral bioavailability.
[0349] The method for preparing these preparations or compositions comprises the step of combining the compound of the present invention with a carrier and optionally one or more auxiliary agents. In general, the preparation is prepared as follows: the compound of the present invention is uniformly and intimately combined with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, the product is shaped.
[0350] Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored base, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base such as gelatin and glycerin, or sucrose and acacia) and / or as a mouthwash, etc., each containing a predetermined amount of a compound of the invention as the active ingredient. A compound of the invention may also be administered as a bolus, electuary or paste.
[0351] In the solid dosage forms of the present invention for oral administration (capsules, tablets, pills, dragees, powders, granules, lozenges, etc.), the active ingredient is mixed with one or more pharmaceutically acceptable carriers (such as sodium citrate or dicalcium phosphate) and / or any of the following substances: (1) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol and / or silicic acid; (2) binders, for example, carboxymethyl cellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or acacia; (3) humectants, such as glycerol; (4) disintegrants, such as agar, calcium carbonate, potato or Tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarders, such as paraffin; (6) absorption promoters, such as quaternary ammonium compounds and surfactants, such as poloxamers and sodium lauryl sulfate; (7) wetting agents, such as cetyl alcohol, glyceryl monostearate, and nonionic surfactants; (8) absorbents, such as kaolin and bentonite; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, zinc stearate, sodium stearate, stearic acid, and mixtures thereof; (10) colorants; and (11) controlled release agents, such as crospovidone or ethylcellulose. In the case of capsules, tablets, and pills, the pharmaceutical composition may also contain a buffer. Solid compositions of a similar type may also be employed as fillers in soft and hard shell gelatin capsules, using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols.
[0352] Tablets can be prepared by compression or molding, optionally with one or more auxiliary agents. Compressed tablets can be prepared using a binder (e.g., gelatin or hydroxypropyl methylcellulose), a lubricant, an inert diluent, a preservative, a disintegrant (e.g., sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), a surfactant or a dispersant. Molded tablets can be prepared by molding a mixture of powdered compounds moistened with an inert liquid diluent in a suitable machine.
[0353] Tablets and other solid dosage forms (such as dragees, capsules, pills and granules) of the pharmaceutical compositions of the present invention may be optionally scored or prepared with coatings and shells (such as enteric coatings and other coatings well known in the art of pharmaceutical formulation). They may also be formulated to provide slow release or controlled release of the active ingredient therein, using, for example, various proportions of hydroxypropylmethylcellulose (to provide the desired release profile), other polymer matrices, liposomes and / or microspheres. They may be formulated (e.g., freeze-dried) for rapid release. They may be sterilized as follows: for example, by filtering through a bacteria-retaining filter, or by a sterilizing agent in the form of a sterile solid composition soluble in sterile water, or by including certain other sterile injectable media before use. These compositions may also optionally contain opacifiers and may have a composition that releases only the active ingredient, or preferably in certain parts of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient may also be present in microcapsule form, if appropriate, with one or more of the above-mentioned excipients.
[0354] Liquid dosage forms for oral administration of the compounds of the present invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage form may also contain an inert diluent commonly used in the art, for example, water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oil (specifically, cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuran alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof.
[0355] Besides inert diluents, the oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
[0356] Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
[0357] Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as suppositories which may be prepared by mixing one or more of the compounds of the invention with one or more suitable non-irritating excipients or carriers including, for example, cocoa butter, polyethylene glycol, suppository wax or salicylates, which are solid at room temperature but liquid at body temperature and therefore will melt in the rectum or vaginal cavity and release the active compounds.
[0358] Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
[0359] Dosage forms for topical or transdermal administration of the compounds of the invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier and with any preservatives, buffers or propellants that may be required.
[0360] Ointments, pastes, creams and gels may contain, in addition to the active compounds of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starches, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid, talc and zinc oxide, or mixtures thereof.
[0361] In addition to the compounds of this invention, powders and sprays may contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or mixtures of these substances. Sprays may additionally contain conventional propellants (such as chlorofluorocarbons) and volatile unsubstituted hydrocarbons, such as butane and propane.
[0362] Transdermal patches have the additional advantage of providing controlled delivery of the compound of the present invention to the body. Such dosage forms can be prepared by dissolving or dispersing the compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound through the skin. Such flux rate can be controlled as follows: a rate-controlled membrane is provided or the compound is dispersed in a polymer matrix or a gel.
[0363] Ophthalmic formulations, eye ointments, powders, solutions, etc. are also contemplated as being within the scope of this invention.
[0364] Pharmaceutical compositions of the present invention suitable for parenteral administration comprise one or more compounds of the present invention and one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders reconstituted into sterile injectable solutions or dispersions immediately before use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents.
[0365] Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by maintaining the required particle size (in the case of dispersions), and by the use of surfactants.
[0366] These compositions can also contain adjuvants such as preservatives, wetting agents, emulsifiers and dispersants. By including various antibacterials and antifungals (for example, parabens, chlorobutanol, phenol sorbic acid, etc.), it is possible to ensure that microorganisms are prevented from acting on the subject compound. It may also be necessary to include isotonic agents such as sugar, sodium chloride, etc. in the compositions. In addition, by including agents such as aluminum monostearate and gelatin that delay absorption, it is possible to achieve the extended absorption of injectable drug forms.
[0367] In some cases, in order to prolong the effect of the drug, it is necessary to slow down the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by using a liquid suspension of crystalline or amorphous materials with poor water solubility. The absorption rate of the drug then depends on its dissolution rate, which in turn can depend on crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is achieved by dissolving or suspending the drug in an oil vehicle.
[0368] Injectable depot forms are prepared by forming a microencapsulation matrix of the subject compound in a biodegradable polymer such as polylactide-polyglycolide. Depending on the ratio of drug to polymer and the properties of the specific polymer employed, the drug release rate can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Injectable depot formulations are also prepared by encapsulating the drug in liposomes or microemulsions that are compatible with body tissues.
[0369] When the compounds of the present invention are administered as medicines to humans and animals, they can be administered as such, or as a pharmaceutical composition containing, for example, 0.1-99% (more preferably, 10-30%) of the active ingredient in combination with a pharmaceutically acceptable carrier.
[0370] The preparations of the invention can be administered orally, parenterally, topically or rectally. They are of course administered in a form suitable for each route of administration. For example, they are administered in tablet or capsule form by injection, inhalation, eye lotion, ointment, suppository, etc., by injection, infusion or inhalation; topically by lotion or ointment; and rectally by suppository. Oral administration is preferred.
[0371] As used herein, the phrases "parenteral administration" and "administered parenterally" refer to modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, and intrasternal injection and infusion.
[0372] As used herein, the phrases "systemic administration," "administered systemically," "peripheral administration," and "peripheral administration" refer to the administration of a compound, drug, or other substance, other than direct administration into the central nervous system, such as subcutaneous administration, so that it enters the patient's system and thereby undergoes metabolism and other similar processes.
[0373] The compounds can be administered to humans and other animals for therapeutic purposes by any suitable route of administration, including orally, nasally (such as by, for example, a spray), rectally, intravaginally, parenterally, intracisternal and topically (such as by powders, ointments or drops, including buccally and sublingually).
[0374] Regardless of the administration route selected, the compound of the present invention, which may be used in a suitable hydrated form, and / or the pharmaceutical composition of the present invention may be formulated into a pharmaceutically acceptable dosage form by conventional methods known to those skilled in the art.
[0375] Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient, composition, and mode of administration that is effective to achieve the desired therapeutic response for a particular patient, without being toxic to the patient.
[0376] The selected dosage level will depend upon a variety of factors, including the activity of the particular compound of the present invention employed, or its ester, salt or amide, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and / or substances used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
[0377] A physician or veterinarian with ordinary skills in the art can easily determine and prescribe the effective amount of the pharmaceutical composition required. For example, a physician or veterinarian can start the dosage of the compound of the invention used in the pharmaceutical composition at a level lower than the required level in order to achieve the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved.
[0378] In general, the suitable daily dose of the compound of the present invention is the amount of the compound: it is the minimum dose that effectively produces a therapeutic effect. Such an effective dose generally depends on the factors described above. Preferably, the compound is administered in an amount of about 0.01 mg / kg to about 200 mg / kg, more preferably about 0.1 mg / kg to about 100 mg / kg, and even more preferably about 0.5 mg / kg to about 50 mg / kg. When the compound described herein is co-administered with other agents (e.g., as a sensitizer), the effective amount may be less than the effective amount when the agent is used alone.
[0379] If desired, the effective daily dose of active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally in unit dosage form.Preferred dosing is once daily.
[0380] The invention further provides a unit dosage form, such as a tablet or capsule, comprising a therapeutically effective amount of a deuterium-enriched piperidinyl-methyl-purineamine or a related compound described herein for the treatment of a disease or condition described herein. Example
[0381] The invention will now be generally described, which will be more readily understood by reference to the following examples, which are included solely for the purpose of illustrating certain aspects and embodiments of the invention and are not intended to limit the invention.
[0382] Example 1-Synthesis of methyl 5-((R)-3-(benzylamino)-3-((S)-2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2,5-difluoro-4-(methoxy-d3)phenyl)isonicotinate
[0383]
[0384] The title compound was prepared using the following procedure.
[0385]
[0386]
[0387] Part 1: Preparation of Compound B
[0388] To a solution of compound A (200 g, 1.00 equiv.) and K2CO3 (330 g, 2.50 equiv.) in DMF (2.0 L) was added CD3I (208 g, 1.50 equiv.) at 0 °C. The mixture was stirred at 20 °C for 16 hours. Then, the reaction mixture was quenched by adding H2O (1.00 L) and extracted with EtOAc (500 mL x 3). The combined organic layers were washed with brine (500 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to produce compound B (190 g, crude) as a white solid. 1 HNMR: (CDCl3, 400MHz) δ7.27 (dd, J=10.0, 6.4Hz, 1H), 6.78 (dd, J=9.6, 7.2Hz, 1H).
[0389] Part 2: Preparation of Compound C
[0390] To a solution of compound B (150 g, 1.00 eq.) and BPD (337 g, 2.00 eq.) in dioxane (1.05 L) was added AcOK (97.7 g, 1.50 eq.) and Pd(dppf)Cl under N2 atmosphere. 2( The resulting mixture was stirred at 90 ° C for 16 hours. Then, the reaction mixture was cooled to 20 ° C and quenched by adding H2O (500 mL), and extracted with EtOAc (500 mL x 3). The combined organic layers were washed with brine (500 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to produce Compound C (200 g, crude) as a white solid. 1 H NMR: (CDCl3, 400MHz) δ7.38 (dd, J=11.2, 5.6Hz, 1H), 6.64 (dd, J=10.0, 6.8Hz, 1H), 1.26 (s, 12H).
[0391] Part 3: Preparation of Compound E
[0392] Compound C (200 g, 1.00 eq.) and compound D (136.8 g, 0.85 eq.) were mixed in dioxane (1.6 L) and water (400 mL). K2CO3 (202 g, 2.00 eq.) and Pd(dppf)Cl were added to the resulting mixture under N2 atmosphere. 2( 53.6 g, 0.05 eq.). The mixture was then stirred at 80 °C for 16 h. The reaction mixture was then cooled to 20 °C and quenched by the addition of H2O (500 mL) and extracted with EtOAc (500 mL x 3). The combined organic layers were washed with brine (500 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to yield Compound E (390 g, crude) as a white solid. 1 H NMR: (D2O, 400MHz) δ8.45 (s, 1H), 7.75 (d, J = 5.2Hz, 1H), 7.39 (dd, J = 12.0, 7.2Hz, 1H), 6.98 (dd, J = 12.4, 7.2Hz, 1H).
[0393] Part 4: Preparation of Compound F
[0394] To a solution of compound E (390 g, 1.00 eq.) in DMF (2.34 L) was added Me2SO4 (105.8 g, 0.70 eq.). The resulting mixture was stirred at 25 °C for 16 hours. The reaction mixture was then poured into H2O (1.00 L) and filtered to remove solids. The filtrate was concentrated under reduced pressure to yield compound F (128 g, crude) as a white solid. 1 H NMR: (CDCl3, 400MHz) δ 8.65 (d, J = 2.0 Hz, 1H), 8.26 (d, J = 6.0 Hz, 1H), 7.81 (dd, J = 12.0, 7.2 Hz, 1H), 6.79 (dd, J = 12.4, 6.8 Hz, 1H), 4.01 (s, 3H). LCMS:ESIMS+1=301.0)
[0395] Part 5: Preparation of Compound H, which has the chemical name 5-((R)-3-(benzylamino)-3-((S)-2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2,5-difluoro-4-(methoxy-d3)phenyl)isonicotinic acid methyl ester
[0396] To a solution of compound F (50.0 g, 1.00 equiv) in NMP (300 mL) was added DIEA (172 g, 8.00 equiv) and compound G (102 g, 1.00 equiv). The resulting mixture was stirred at 100 ° C for 12 hours. Then, the reaction mixture was cooled to 20 ° C and quenched by adding H2O (500 mL) and extracted with EtOAc (100 mL x 2). H2O (300 mL) was added to the combined organic layer and 35% HCl was added dropwise at 20 ° C to adjust the pH to 1-2, thereby providing a suspension. The suspension was filtered and the resulting filter cake was dissolved with 2-MeTHF (500 mL). A 20% mixed solvent of KHCO3 / H2O (500 mL) was added to the solution and extracted with 2-MeTHF (200 mL x 3). The 2-MeTHF phase was washed with brine (500 mL.times.3), dried over Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure to give Compound H (85.0 g) as a yellow oil. 1H NMR: (CDCl3, 400MHz) δ8.38(s,1H),7.85(s,1H),7.69(dd,J=12.4,7.6Hz,1H),7.28-7.17(m,5H),6.65(dd,J=12.0,6.8Hz,1H),5.92(td,J =55.2,3.6Hz,1H),3.71-3.55(m,6H),3.20-3.17(m,2H),2.96(d,J=11.6Hz,1H),2.85-2.77(m,1H),2.05-2.01(m,1H),1.68-1.64(m,1H). LCMS:ESI MS+1=550.3.
[0397] Example 2-Synthesis of Compound I-1
[0398]
[0399] The title compound was prepared using the following procedure.
[0400]
[0401]
[0402] Part 1: Preparation of Compound O
[0403] To a solution of compound H (33.0 g, 1.00 equivalent) in THF (297 mL) and MeOH (33.0 mL) was added LiBH4 (2.00 M, 59.9 mL, 2.00 equivalent) at 20 ° C, and then the reaction mixture was stirred at 40 ° C for 3 hours. Then, the reaction was quenched with additional water (100 mL), and the resulting mixture was extracted with EtOAc (50.0 mL x 3). The organic phase of the mixture was separated and washed with brine (200 mL), dried with anhydrous Na2SO4, and concentrated under vacuum to provide compound O (29.0 g) as a white solid. 1HNMR:(DMSO-d,400MHz)δ8.35(s,1H),7.90(s,1H),7.75-7.73(m,1H),7.38-7.30(m,4H) ,7.24-7.22(m,2H),6.26(t,J=55.2Hz,1H),5.72-7.71(d,J=6.4Hz,1H),5.41(t,J=6.4Hz ,1H),4.59-4.57(d,J=5.6Hz,2H),3.80-3.76(m,2H),3.66-3.64(m,1H),3.12(d,J=11.6 Hz, 1H), 2.93 (d, J = 10.8Hz, 1H), 2.71-2.69 (m, 1H), 2.22-2.21 (m, 1H), 1.84-1.69 (m, 4H). LCMS:ESI MS+1=523.2.
[0404] Part 2: Preparation of Compound P
[0405] To a solution of compound O (28.0 g, 1.00 equiv.) in DCM (280 mL) was added SOCl2 (10.96 g, 1.60 equiv.) portionwise at 0 ° C, and the reaction mixture was then stirred at 0 ° C for 2 hours. H2O (20.0 mL) was added to the reaction mixture, and the resulting mixture was stirred at 25 ° C for 16 hours. Then, the reaction mixture was slowly quenched by adding Na2CO3 aqueous solution (100 mL, 10%). The resulting mixture was extracted with DCM (100 mL x 2). The combined organic layers were washed with brine (200 mL x 2), dried over Na2SO4, and concentrated under vacuum to provide compound P (29.0 g) as a yellow solid. 1 H NMR: (CDCl3, 400MHz) δ8.38 (s, 1H), 7.75 (s, 1H), 7.70 (dd, J = 12.4, 7.6Hz, 2H), 7.2 8-7.18(m,5H),6.67(dd,J=12.4,7.2Hz,1H),5.95(td,J=55.2,3.2Hz,1H),4.56(d, J=12.0Hz,1H),4.49(d,J=12.0Hz,1H),3.74-3.62(m,3H),3.06-3.05(m,3H),2.81- 2.79(m,1H),2.06-2.02(m,1H),1.92(s,1H),1.84-1.80(m,2H),1.74-1.71(m,1H). LCMS:ESIMS+1=541.2
[0406] Part 3: Preparation of Compound Q
[0407] To a solution of compound P (29.0 g, 1.00 equiv) and compound K (18.0 g, 1.30 equiv) in DMA (174 mL) was added KCO (14.8 g, 2.00 equiv). The resulting mixture was stirred at 20 ° C for 12 hours. Then, the reaction mixture was quenched by adding H O (200 mL) at 0 to 5 ° C, and then extracted with EtOAc (100 mL x 3). The combined organic layer was washed with brine (200 mL x 4), dried over Na SO, filtered, and concentrated under vacuum to provide a residue. The residue was purified by column chromatography to provide compound Q (19.8 g) as a yellow solid.
[0408] Part 4: Preparation of Compound R
[0409] A solution of compound Q (19.8 g, 1.00 equiv.) in TFA (59.4 mL) and DCM (118 mL) was stirred at 40 °C for 16 hours. The reaction mixture was then concentrated under reduced pressure to remove TFA and DCM. The resulting residue was diluted with MeOH (40.0 mL) and then poured into a Na2CO3 aqueous solution (50.0 mL). Solids precipitated from the mixture; the solids were collected by filtration. The filter cake was washed with MeOH and dried under vacuum to provide compound R (16.0 g, crude) as a white solid. 1 H NMR:(DMSO-d,400MHz)δ8.84-8.79(br s,1H),8.55(s,1H),8.23(s,1H),8.06(s,1H),7.69(dd,J=12.4,7.6Hz,1H),7.54-7.53(m,2H),7.36- 7.25(m,5H),7.13(dd,J=12.8,7.6Hz,1H),7.00(s,1H),6.46(m,1H),5.81-5.74(m,1H),5.57-5.53(br d,J=16.0Hz,2H),4.42-4.30(m,3H),3.50-3.45(m,2H),3.00(m,2H),2.82(m,1H),2.05-1.90(m,4H),1.75(m,1H). LCMS:ESIMS+1=640.4
[0410] Part 5: Preparation of Compound I-1
[0411] Pd(OH)2 (1.40 g, 10%) and TFA (7.48 g, 3.00 eq.) were added to a solution of compound R (14.00 g, 1.00 eq.) in THF (70.0 mL) under N2 atmosphere. The resulting suspension was degassed and flushed with H2 3 times. The resulting mixture was stirred at 20 ° C for 16 hours under H2 (15 Psi). Then, the reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to provide a residue. The residue was purified by preparative HPLC to provide compound I-1 (6.70 g) as an off-white solid. 1 H NMR: (DMSO-d, 400MHz) δ8.49(s,1H),8.26(s,1H),8.11(s,1H),7.71-7.66(m,1H),7.29(s,1H),7.13 -7.08(m,1H),6.92(s,1H),6.18(t,J=56.4Hz,1H),5.71(d,J=4.8Hz,1H),5.56-5.43(m,2H),3.78(br s,1H),3.10(d,J=10.8Hz,2H),3.08(br s,1H),2.91(br s,1H),2.77(d,J=7.6Hz,1H),1.89-1.72(m,4H),1.47(s,1H). MS (ES API+), 550.0, calcd. 550.2 (M+H+).
[0412] Example 3-Synthesis of Compound I-2
[0413]
[0414] The title compound was prepared using the following procedure.
[0415]
[0416]
[0417] Part 1: Preparation of Compound I
[0418] To a solution of compound H (70.0 g, 1.00 eq.) in THF (490 mL) was added LiAlD4 (7.24 g, 1.50 eq.) at 20-30 °C, and the reaction was stirred at 40 °C for 3 hours. Then, the reaction was quenched with D2O (200 mL) and extracted with EtOAc (100 mL x 3). The organic phase was washed with brine (500 mL), dried over anhydrous Na2SO4 and concentrated under vacuum to provide compound I (63.0 g, crude) as a yellow solid. 1HNMR: (CDCl3, 400MHzδ8.36(s,1H),7.73(s,1H),7.69(dd,J=14.8,7.6Hz,1H),7.28-7.19(m,6H),6.67(dd,J=12.0,6.8Hz,1H),5.96(td,J=56.0,4 .0Hz,1H),3.72-3.64(m,2H),3.10-3.07(m,1H),3.03-2.96(m,2H),2.83- 2.81(m,1H),1.97-1.95(m,1H),1.84-1.74(m,3H).LCMS:ESIMS+1=525.2)
[0419] Part 2: Preparation of Compound J
[0420] To a solution of compound I (54.0 g, 1.00 equiv.) in DCM (540 mL) was added SOCl2 (18.00 g, 1.50 equiv.) portionwise at 0 ° C. The reaction mixture was then stirred at 0 ° C for 2 hours. Next, water (60.0 mL) was added to the reaction mixture, and the resulting mixture was stirred at 25 ° C for 16 hours. The reaction mixture was then slowly quenched with Na2CO3 aqueous solution (200 mL, 10%) and extracted with DCM (100 mL x 3). The combined organic layers were washed with brine (200 mL x 2), dried over Na2SO4, and concentrated under vacuum to provide compound J (55.0 g, crude) as a yellow solid. 1 H NMR: (CDCl3, 400MHz) δ8.38(s,1H),7.74(s,1H),7.71(dd,J=14.4,6.8Hz,1H),7.28-7.18(m,5H),6.68(dd,J=12.0,6.8Hz,1H) ,5.97(td,J=55.2,3.2Hz,1H),3.77-3.61(m,3H),3.06-3.05(m,3H),2.82-2.79(m,1H),2.05-2.01(m,1H),1.82-1.75(m,3H). LCMS:ESI MS+1=543.1
[0421] Part 3: Preparation of Compound L
[0422] To a solution of compound J (50.0 g, 1.00 equiv) and compound K (40.0 g, 1.30 equiv) in DMA (300 mL) was added KCO (25.4 g, 2.00 equiv). The resulting mixture was stirred at 20 ° C for 12 hours. Then, the reaction mixture was quenched by adding D2O (500 mL), and then extracted with EtOAc (100 mL x 3). The combined organic layer was washed with brine (200 mL x 4), dried over Na2SO4, and filtered. The resulting residue was purified by column chromatography to provide compound L (60.0 g) as a yellow solid. 1 H NMR: (CDCl3, 400MHz) δ8.69(s,1H),8.48(s,1H),7.95(s,1H),7.66(dd,J=12.4,7.2Hz,1H),7.29-7.15(m,6H),6.55(dd,J=12.4 ,7.2Hz,1H),6.02(t,J=56.0Hz,1H),3.80-3.71(m,2H),3.31-3.30(m,1H),3.00-2.88(m,3H),1.85-1.78(m,4H),1.36(s,18H).
[0423] Part 4: Preparation of Compound M
[0424] Compound L (30.0 g, 1.00 equivalent) was mixed with DCM (180 mL), and TFA (90.0 mL) was then added. The resulting mixture was stirred at 40 ° C for 16 hours. Then, the reaction mixture was concentrated under reduced pressure to remove TFA and DCM. The resulting residue was diluted with MeOD (100 mL) and then poured into the Na2CO3 aqueous solution (200 mL). Solid precipitated out, which was collected by filtration. The filter cake was washed with MeOH and dried under vacuum to provide compound M (27.0 g, crude) as a white solid. 1 H NMR: (DMSO-d, 400MHz) δ8.52 (s, 1H), 8.21 (s, 1H), 7.99 (s, 1H), 7.68 (dd, J = 12. 4,7.2Hz,1H),7.40-7.11(m,8H),6.96(s,1H),6.28(t,J=54.8Hz,1H),5.84(br s,1H),4.01-3.95(m,2H),3.86-3.72(m,1H),3.06-3.02(m,2H),2.85-2.83(m,1H),2.44-2.43(m,1H),1.75-1.73(m,4H). LCMS:ESIMS+1=642.4)
[0425] Part 5: Preparation of Compound I-2
[0426] Pd(OH)2(6.00g, 10.0%) and TFA(14.4g, 3.00 equiv) were added to a solution of compound M (27.0g crude, 1.00 equiv) in THF (135mL) under N2 atmosphere. The suspension was degassed and rinsed with H2 3 times. The mixture was stirred at 20°C for 16 hours under H2 (15Psi). Then, the reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to provide a residue. The residue was dissolved with EtOH (40.0mL), and then a solution of a lower alkyl dicarboxylic acid in D2O (7.50mL) was added dropwise. The mixture was stirred at 50°C for 16 hours. Then, the mixture was filtered, and the filter cake was concentrated. The filter cake was neutralized using Na2CO3 (50.0mL), and then filtered to provide compound I-2 as a white solid. 1 H NMR: (DMSO-d, 400 MHz) δ 8.50 (s, 1H), 8.26 (s, 1H), 8.13 (s, 1H), 7.71-7.66 (m, 1H), 7.32 (s, 1H), 7.14-7.09 (m, 1H), 6.98 (s, 1H), 6.21 (td, J = 55.6, 3.6 Hz, 1H), 3.88-3.81 (m, 2H), 3.12 (d, J = 12.0 Hz, 1H), 3.04-3.02 (m, 1H), 2.93-2.85 (m, 2H), 1.89-1.72 (m, 3H), 1.58-1.56 (m, 1H). MS (TOF ES+), 552.2495.552.2507 calculated values (M+H+).
[0427] Incorporated by Reference
[0428] The entire disclosure of each patent document and scientific article mentioned herein is incorporated by reference for all purposes.
[0429] Equivalent solution
[0430] The present invention can be implemented in other specific forms without departing from its spirit or essential characteristics. Therefore, the aforementioned embodiments should be regarded as exemplary in all aspects, rather than limiting the invention described herein. Thus, the scope of the present invention is determined by the appended claims, rather than by the aforementioned description, and all changes within the meaning and scope of the equivalent schemes of the claims are intended to be included therein.
Claims
1. A compound represented by formula I: or a pharmaceutically acceptable salt thereof; wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 are independently H or Z; and Z is H or D, provided that the abundance of deuterium in Z is at least 75%; The prerequisite is that R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 At least one of them is Z.
2. The compound of claim 1, wherein the compound is a compound of formula I.
3. The compound of claim 1, wherein the compound is represented by Formula IA: or a pharmaceutically acceptable salt thereof; wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 are independently H or Z; and Z is H or D, provided that the abundance of deuterium in Z is at least 75%; The prerequisite is that R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 At least one of them is Z.
4. The compound of claim 3, wherein the compound is a compound of formula IA.
5. The compound according to any one of claims 1 to 4, wherein R 21 It’s Z.
6. The compound of any one of claims 1 to 4, wherein R 21 It's H.
7. Compounds represented by formula II: or a pharmaceutically acceptable salt thereof; wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 are independently H or Z; and Z is H or D, provided that the abundance of deuterium in Z is at least 75%.
8. The compound of claim 7, wherein the compound is a compound of formula II.
9. The compound of claim 7, wherein the compound is represented by formula II-A: or a pharmaceutically acceptable salt thereof; wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 are independently H or Z; and Z is H or D, provided that the abundance of deuterium in Z is at least 75%.
10. The compound of claim 9, wherein the compound is a compound of formula II-A.
11. The compound of any one of claims 7 to 10, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 At least one of them is Z.
12. The compound of any one of claims 1 to 11, wherein R 1 , R 2 and R 3 It’s Z.
13. The compound of any one of claims 1 to 11, wherein R 1 , R 2 and R 3 It's H.
14. The compound of any one of claims 1 to 13, wherein R 4 , R 5 , R 6 and R 7 It's H.
15. The compound of any one of claims 1 to 14, wherein R 8 and R 9 It’s Z.
16. The compound of any one of claims 1 to 14, wherein R 8 and R 9 It's H.
17. The compound of any one of claims 1 to 16, wherein R 10 and R 11 It's H.
18. The compound of any one of claims 1 to 17, wherein R 12 and R 13 It’s Z.
19. The compound of any one of claims 1 to 17, wherein R 12 and R 13 It's H.
20. The compound of any one of claims 1 to 19, wherein R 14 , R 15 , R 16 and R 17 It's H.
21. The compound of any one of claims 1 to 20, wherein R 18and R 19 It’s Z.
22. The compound of any one of claims 1 to 20, wherein R 18 and R 19 It's H.
23. The compound of any one of claims 1 to 22, wherein R 20 It’s Z.
24. The compound of any one of claims 1 to 22, wherein R 20 It's H.
25. The compound of any one of claims 1-24, wherein the abundance of deuterium in Z is at least 90%.
26. The compound of any one of claims 1-24, wherein the abundance of deuterium in Z is at least 95%.
27. The compound of any one of claims 1-26, wherein the compound has an enantiomeric excess of at least 85%.
28. The compound of any one of claims 1-26, wherein the compound has an enantiomeric excess of at least 90%.
29. The compound of any one of claims 1-26, wherein the compound has an enantiomeric excess of at least 95%.
30. A compound of Table 1 or 2 herein, or a pharmaceutically acceptable salt thereof.
31. A pharmaceutical composition comprising the compound of any one of claims 1 to 30 and a pharmaceutically acceptable carrier.
32. A method for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2), the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1-30 to treat the disease or condition.
33. The method of claim 32, wherein the disease or condition mediated by NSD2 is cancer.
34. The method of claim 32, wherein the disease or condition mediated by NSD2 is selected from the group consisting of solid tumors, leukemia, myeloma, lymphoma, and hypertension.
35. The method of claim 32, wherein the disease or condition mediated by NSD2 is breast cancer, cervical cancer, skin cancer, ovarian cancer, gastric cancer, prostate cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, head and neck cancer, peripheral nerve sheath tumors, osteosarcoma, multiple myeloma, neuroblastoma, leukemia, non-Hodgkin's lymphoma, or pulmonary hypertension.
36. The method of claim 32, wherein the disease or condition mediated by NSD2 is acute lymphoblastic leukemia, cutaneous squamous cell carcinoma, or mantle cell lymphoma.
37. The method of any one of claims 32-36, wherein the subject is a human.
38. A method of inhibiting the activity of nuclear SET domain-containing protein 2 (NSD2), the method comprising contacting NSD2 with an effective amount of a compound according to any one of claims 1 to 30 to inhibit the activity of NSD2.
